image_name stringlengths 68 68 | type stringclasses 2
values | gt_table stringlengths 116 12.6k | table_fragment_1 stringlengths 43 8.42k | table_fragment_2 stringlengths 39 8.21k |
|---|---|---|---|---|
65a9db96f20341fac5cbb0ce49a1dddd53bc0d487bd4ecad7cc54aad5f1a835e.png | complex | <table><tr><td></td><td colspan="3">Mean (SD)</td><td><i>P</i> value</td></tr><tr><td></td><td>1st trimester</td><td>2nd trimester</td><td>3rd trimester</td><td></td></tr><tr><td>Completion time (minutes)</td><td>21.8 (7.5)</td><td>19.2 (6.8)</td><td>16.3 (5.1)</td><td>< 0.0001</td></tr><tr><td>Reported meals (N)</t... | <table><tr><td></td><td colspan="3">Mean (SD)</td><td>P value</td></tr><tr><td></td><td>1st trimester</td><td>2nd trimester</td><td>3rd trimester</td><td></td></tr><tr><td>Completion time (minutes)</td><td>21.8 (7.5)</td><td>19.2 (6.8)</td><td>16.3 (5.1)</td><td>< 0.0001</td></tr><tr><td>Reported meals (N)</td><td>5.1 ... | <table><tr><td>ted items (N)</td><td>4.0)</td><td>3 (4.1)</td><td>4 (4.0)</td><td>25</td></tr></table> |
eda30bec147b8384215b0cb4527ae995f1ddefa464c794e2b0446416584e5ab6.png | complex | <table><tr><td rowspan="2">Complications</td><td colspan="2">Group 1</td><td colspan="2">Group 2</td></tr><tr><td>To adult</td><td>To pediatrics</td><td><i>En-bloc</i></td><td>Single</td></tr><tr><td>Renal vein thrombosis</td><td>—</td><td>1 (early nephrectomy)</td><td>—</td><td>2 (graft loss)</td></tr><tr>... | <table><tr><td rowspan="2">Complications</td><td colspan="2">Group 1</td><td colspan="2">Group 2</td></tr><tr><td>To adult</td><td>To pediatrics</td><td>En-bloc</td><td>Single</td></tr><tr><td>Renal vein thrombosis</td><td>—</td><td>1 (early nephrectomy)</td><td>—</td><td>2 (graft loss)</td></tr><tr><td>Renal arterial ... | <table><tr><td>Significant lymphocele</td><td>1 (percutaneous drainage)</td><td>—</td><td>1 (percutaneous drainage)</td><td>1</td></tr><tr><td>Ureteral fistula</td><td>1 (surgical repair)</td><td>—</td><td>—</td><td>1 (surgical repair)</td></tr><tr><td>Ureteral stenosis</td><td>1 (surgical repair)</td><td>—</td><td>—</... |
558cef7f8cbb64547304d46decd7f1ab1fdd6238399d3359872789d16e4ccc02.png | simple | <table><tr><td></td><td>n of cases</td><td>IPAT</td><td>PSP</td><td>IPAT & PSP</td></tr><tr><td>CF and RP/CP</td><td>48</td><td>14 (29.2)</td><td>11 (22.9)</td><td>19 (39.6)</td></tr><tr><td>CF without pancreatitis</td><td>35</td><td>2 (5.7)</td><td>3 (8.5)</td><td>4 (11.4)</td></tr><tr><td>healthy subjects</td><td... | <table><tr><td></td><td>n of cases</td><td>IPAT</td><td>PSP</td><td>IPAT & PSP</td></tr><tr><td>CF and RP/CP</td><td>48</td><td>14 (29.2)</td><td>11 (22.9)</td><td>19 (39.6)</td></tr></table> | <table><tr><td>CF without pancreatitis</td><td>35</td><td>2 (5.7)</td><td>3 (8.5)</td><td>4 (11.4)</td></tr><tr><td>healthy subjects</td><td>80</td><td>3 (3.8)</td><td>8 (10)</td><td>11 (13.7)</td></tr><tr><td>Chi square and (p)</td><td></td><td>20.4 (p < 0.001)</td><td>4.39 (p = 0.11)</td><td>14.5 (p < 0.001)</td></tr... |
6a33c34ca0c50d1a11c80976ca9821c9565e940703c5d82b19e32d7b76f4dad7.png | simple | <table><tr><td>Gene</td><td>F/R</td><td>Primer sequence</td><td>Position</td><td>Tm</td></tr><tr><td>PEPT1</td><td>Forward</td><td>CCCTGAAGTGAAGGTGTTTGAAGATA</td><td>1772–1797</td><td>60.6</td></tr><tr><td>NM_005073</td><td>Reverse</td><td>GAATTGGCCCCTGACATGAA</td><td>2168–2188</td><td>59.3</td></tr><tr><td... | <table><tr><td>Gene</td><td>F/R</td><td>Primer sequence</td><td>Position</td><td>Tm</td></tr><tr><td>PEPT1</td><td>Forward</td><td>CCCTGAAGTGAAGGTGTTTGAAGATA</td><td>1772–1797</td><td>60.6</td></tr><tr><td>NM_005073</td><td>Reverse</td><td>GAATTGGCCCCTGACATGAA</td><td>2168–2188</td><td>59.3</td></tr><tr><td>PEPT2</td><... | <table><tr><td>Gene</td><td>F/R</td><td>Primer sequence</td><td>Position</td><td>Tm</td></tr><tr><td>NM_001012515</td><td>Reverse</td><td>CTAAATAACACCCTCTCCACATCG</td><td>1462–1485</td><td>57.8</td></tr><tr><td>ABCG2</td><td>Forward</td><td>CTAAGCAGGGACGAACAATCATC</td><td>1188–1210</td><td>58.8</td></tr><tr><td>NM_0048... |
cc110b00e92f29f012284b5756167319ce2118f44ec1d6cdaa820b6fcdc0c107.png | simple | <table><tr><td></td><td>LFD</td><td>LFD+NDEA</td><td>HFD</td><td>HFD+NDEA</td><td>F-Ratio</td><td>P-Value</td></tr><tr><td>AβPP</td><td>4.392 ± 0.423</td><td>3.966 ± 0.458</td><td>3.026* ± 0.215</td><td>3.228 ± 0.299</td><td>3.099</td><td>0.039</td></tr><tr><td>Tau</td><td>3.380 ± 0.272</t... | <table><tr><td></td><td>LFD</td><td>LFD+NDEA</td><td>HFD</td><td>HFD+NDEA</td><td>F-Ratio</td><td>P-Value</td></tr><tr><td>AβPP</td><td>4.392 ± 0.423</td><td>3.966 ± 0.458</td><td>3.026* ± 0.215</td><td>3.228 ± 0.299</td><td>3.099</td><td>0.039</td></tr><tr><td>Tau</td><td>3.380 ± 0.272</td><td>2.689 ± 0.255</td><td>3.... | <table><tr><td></td><td>LFD</td><td>LFD+NDEA</td><td>HFD</td><td>HFD+NDEA</td><td>F-Ratio</td><td>P-Value</td></tr><tr><td>IL6</td><td>0.052 ± 0.006</td><td>0.045 ± 0.006</td><td>0.050 ± 0.005</td><td>0.034 ± 0.005</td><td></td><td></td></tr><tr><td>TNF-α</td><td>0.022 ± 0.002</td><td>0.035 ± 0.005</td><td>0.034 ± 0.00... |
b8a9a2b2c4bb3514a6d944043ebce68d58ca1a63f27d87395cf72d679b249b63.png | simple | <table><tr><td></td><td>Pain score ribs</td><td>Pain score iliac crest</td></tr><tr><td>Hospital admission, oral analgesics</td><td>5</td><td>Not applicable</td></tr><tr><td>Pre-operative, with epidural catheter</td><td>3-6</td><td>Not applicable</td></tr><tr><td>Post-operative day 3, with epidural catheter</td><td>1-2... | <table><tr><td></td><td>Pain score ribs</td><td>Pain score iliac crest</td></tr><tr><td>Hospital admission, oral analgesics</td><td>5</td><td>Not applicable</td></tr></table> | <table><tr><td></td><td>Pain score ribs</td><td>Pain score iliac crest</td></tr><tr><td>Pre-operative, with epidural catheter</td><td>3-6</td><td>Not applicable</td></tr><tr><td>Post-operative day 3, with epidural catheter</td><td>1-2</td><td>4-5</td></tr><tr><td>Discharge home, oral analgesics</td><td>1-2</td><td>3-5<... |
6fef4dad16957411564704d941462ecda33a0ba75e74072904aff01e3bdaf310.png | complex | <table><tr><td>Data set</td><td><i>n</i></td><td>MI Re</td><td>KNNI Re</td><td>SVRI Re</td><td>ELMI {Re, Ri}</td></tr><tr><td rowspan="3">Breast</td><td>3</td><td>4.79%</td><td>4.86%</td><td>4.71%</td><td>{4.52%, 3.18%}</td></tr><tr><td>5</td><td>8.23%</td><td>8.38%</td><td>5.96%</td><td>{4.90%, 3.31%}</td></tr><tr><td... | <table><tr><td>Data set</td><td>n</td><td>MI Re</td><td>KNNI Re</td><td>SVRI Re</td><td>ELMI {Re, Ri}</td></tr><tr><td rowspan="3">Breast</td><td>3</td><td>4.79%</td><td>4.86%</td><td>4.71%</td><td>{4.52%, 3.18%}</td></tr><tr><td>5</td><td>8.23%</td><td>8.38%</td><td>5.96%</td><td>{4.90%, 3.31%}</td></tr><tr><td>7</td>... | <table><tr><td>Data set</td><td>n</td><td>MI Re</td><td>KNNI Re</td><td>SVRI Re</td><td>ELMI {Re, Ri}</td></tr><tr><td>Iris</td><td>3</td><td>65.49%</td><td>21.06%</td><td>12.89%</td><td>{12.92%, 9.23%}</td></tr><tr><td rowspan="3">Seeds</td><td>2</td><td>21.05%</td><td>12.38%</td><td>9.26%</td><td>{9.47%, 4.13%}</td><... |
635cc3ba334ce88f71af9f83abf961b4d623bcfdf423de17efd679ea28cdde71.png | simple | <table><tr><td> </td><td>Control group</td><td>LNM group</td><td><i>P</i></td></tr><tr><td>Initial visual ID of RLN (%)</td><td>179/185 (96.8%)</td><td>152/156 (97.4%)</td><td>0.76<sup>a</sup></td></tr><tr><td>Final ID of RLN (%)</td><td>179/185 (96.8%)</td><td>156/156 (100%)</td><td>0.03<sup>a</sup></td></tr><tr><td><... | <table><tr><td></td><td>Control group</td><td>LNM group</td><td>P</td></tr><tr><td>Initial visual ID of RLN (%)</td><td>179/185 (96.8%)</td><td>152/156 (97.4%)</td><td>0.76a</td></tr><tr><td>Final ID of RLN (%)</td><td>179/185 (96.8%)</td><td>156/156 (100%)</td><td>0.03a</td></tr></table> | <table><tr><td></td><td>Control group</td><td>LNM group</td><td>P</td></tr><tr><td>P</td><td>—</td><td>0.12a</td><td>—</td></tr><tr><td>Initial visual ID of EBSLN (%)</td><td>73/185 (39.5%)</td><td>67/156 (42.9%)</td><td>0.51</td></tr><tr><td>Final ID of EBSLN (%)</td><td>73/185 (39.5%)</td><td>118/156 (75.6%)</td><td>... |
8d5d00736b66b9ff93c1427013f5e86057e07b7e842871b4b61bdffb22b32e2f.png | simple | <table><tr><td>Algorithm</td><td><i>precision</i></td><td><i>recall</i></td><td><i>f-measure</i></td></tr><tr><td>SHC[31,32]</td><td>0.4447</td><td>0.3430</td><td>0.3873</td></tr><tr><td>SC[13]</td><td>0.3612</td><td>0.3555</td><td>0.3584</td></tr><tr><td>MCL[12]</td><td>0.3569</td><td>0.3879</td><td>0.3717</td></tr><t... | <table><tr><td>Algorithm</td><td>precision</td><td>recall</td><td>f-measure</td></tr><tr><td>SHC[31,32]</td><td>0.4447</td><td>0.3430</td><td>0.3873</td></tr><tr><td>SC[13]</td><td>0.3612</td><td>0.3555</td><td>0.3584</td></tr><tr><td>MCL[12]</td><td>0.3569</td><td>0.3879</td><td>0.3717</td></tr><tr><td>Newman[8]</td><... | <table><tr><td>ISHC</td><td>0.6624</td><td>0.3620</td><td>0.4673</td></tr></table> |
0f3babdfcf18c2eb8150db565fa749c992de97d407bc2d1786698557ec0acb42.png | simple | <table><tr><td>Class</td><td><i>T. urticae</i></td><td><i>P. ulmi</i></td><td><i>P. citri</i></td></tr><tr><td>A</td><td>18</td><td>10</td><td>7</td></tr><tr><td>B</td><td>6</td><td>4</td><td>4</td></tr><tr><td>C</td><td>78</td><td>28</td><td>26</td></tr><tr><td>D</td><td>2</td><td>2</td><td>2</td></tr><tr><td>E</td><t... | <table><tr><td>Class</td></tr><tr><td>A</td></tr><tr><td>B</td></tr><tr><td>C</td></tr><tr><td>D</td></tr><tr><td>E</td></tr><tr><td>F</td></tr><tr><td>G</td></tr><tr><td>H</td></tr><tr><td>Total</td></tr></table> | <table><tr><td>T. urticae</td><td>P. ulmi</td><td>P. citri</td></tr><tr><td>18</td><td>10</td><td>7</td></tr><tr><td>6</td><td>4</td><td>4</td></tr><tr><td>78</td><td>28</td><td>26</td></tr><tr><td>2</td><td>2</td><td>2</td></tr><tr><td>2</td><td>2</td><td>2</td></tr><tr><td>6</td><td>6</td><td>6</td></tr><tr><td>23</t... |
b906d1bbfce03cfd533b507630f9b55b745f191a54830bde640b1e9c1bf81f0a.png | complex | <table><tr><td rowspan="2" colspan="2"> </td><td colspan="2">Vascularization ≤ 1 point</td></tr><tr><td>No</td><td>Yes</td></tr><tr><td rowspan="2">Target IOP not reached</td><td>No</td><td>39</td><td>3</td></tr><tr><td>Yes</td><td>10</td><td>5</td></tr><tr><td>Agreement</td><td>Kappa</td><td> </td><td>.31</td></... | <table><tr><td colspan="2"></td><td colspan="2">Vascularization ≤ 1 point</td></tr></table> | <table><tr><td colspan="2"></td><td>No</td><td>Yes</td></tr><tr><td rowspan="2">Target IOP not reached</td><td>No</td><td>39</td><td>3</td></tr><tr><td>Yes</td><td>10</td><td>5</td></tr><tr><td>Agreement</td><td>Kappa</td><td></td><td>.31</td></tr></table> |
2e41f56acb9440f27298eaade0bc1d70ab2f12ac2b1f9d1928e6f6dcc58a7e40.png | complex | <table><tr><td>Dependent measure</td><td>Condition</td><td colspan="3">Descriptive statistics</td><td colspan="9">Inferential statistics</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td colspan="3">Group</td><td colspan="3">Condition</td><td colspan="3">Group × condition</td></tr><tr><td></td><td></td... | <table><tr><td>Dependent measure</td><td>Condition</td><td colspan="3">Descriptive statistics</td></tr><tr><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>ASD (n = 19)</td><td>Comparison (n = 20)</td><td>Total</td></tr><tr><td rowspan="4">Proportion of time in target quadrant</td><td>Visible... | <table><tr><td colspan="9">Inferential statistics</td></tr><tr><td colspan="3">Group</td><td colspan="3">Condition</td><td colspan="3">Group × condition</td></tr><tr><td>F(1, 37)</td><td>p</td><td>r</td><td>F(1, 37)</td><td>p</td><td>r</td><td>F(1, 37)</td><td>p</td><td>r</td></tr><tr><td></td><td></td><td></td><td></t... |
968858b34f78333ba9ee1d1116ec17588e4442cc924e22e0e066d81dacfd9b78.png | complex | <table><tr><td></td><td></td><td colspan="3">Temperature shift</td><td colspan="3">Blood feeding</td><td colspan="2">Temperature shift + Blood feeding</td></tr><tr><td></td><td></td><td>Microarray</td><td colspan="2">RT-qPCR</td><td>Microarray</td><td colspan="2">RT-qPCR</td><td colspan="2">RT-qPCR</td></tr><tr><td>Gen... | <table><tr><td></td><td></td><td colspan="3">Temperature shift</td><td colspan="3">Blood feeding</td><td colspan="2">Temperature shift + Blood feeding</td></tr><tr><td></td><td></td><td>Microarray</td><td colspan="2">RT-qPCR</td><td>Microarray</td><td colspan="2">RT-qPCR</td><td colspan="2">RT-qPCR</td></tr><tr><td>Gen... | <table><tr><td>A1G_02785</td><td>site-specific tyrosine recombinase XerD</td><td>1.53 (1.53; 1.53)</td><td>1.86</td><td>0.0000</td><td>-2.69 (-2.52; -2.87)</td><td>-4.35</td><td>0.0000</td><td>-2.27</td><td>0.0000</td></tr><tr><td>A1G_03790</td><td>cell surface antigen</td><td>-1.79 (-1.99; -1.60)</td><td>-1.96</td><td... |
e54a466fa83106cc042334a74ffcf1c80a8da360d5b00d03707d3fc09d4ecf6d.png | complex | <table><tr><td>Time period 6 month intervals</td><td>Mean proportion of CVD services delivered</td><td>Difference from baseline</td><td>t-test</td><td><i>P*</i></td></tr><tr><td>Baseline</td><td>0.29</td><td>-</td><td>-</td><td>-</td></tr><tr><td>2</td><td>0.26</td><td>-0.04</td><td>-0.81</td><td>0.42</td></tr><tr><td>... | <table><tr><td>Time period 6 month intervals</td><td>Mean proportion of CVD services delivered</td><td>Difference from baseline</td><td>t-test</td><td>P*</td></tr><tr><td>Baseline</td><td>0.29</td><td>-</td><td>-</td><td>-</td></tr><tr><td>2</td><td>0.26</td><td>-0.04</td><td>-0.81</td><td>0.42</td></tr><tr><td>3</td><... | <table><tr><td>8</td><td>0.42</td><td>0.13</td><td>2.55</td><td>0.01</td></tr><tr><td>9</td><td>0.72</td><td>0.43</td><td>8.48</td><td>< 0.001</td></tr><tr><td>10</td><td>0.62</td><td>0.33</td><td>6.42</td><td>< 0.001</td></tr><tr><td>11</td><td>0.52</td><td>0.23</td><td>4.25</td><td>< 0.001</td></tr><tr><td>12</td><td... |
cef9439ca8e8df66a2b7bc8de5c908cd5a974daa681878e8e0ef2a63d84f9012.png | simple | <table><tr><td>Assembler</td><td>Sequencing</td><td>Strains</td><td>Insert size</td><td>Read length (bp)</td><td>Number of reads</td><td>Raw read coverage</td><td>Assembled bases (Mb)</td><td>Contig coverage</td><td>Contig N50</td></tr><tr><td>FuzzyPath</td><td>Illumina</td><td>CAST/Ei</td><td>200 bp</td><td>36</td><td... | <table><tr><td>Assembler</td><td>Sequencing</td><td>Strains</td><td>Insert size</td><td>Read length (bp)</td><td>Number of reads</td><td>Raw read coverage</td><td>Assembled bases (Mb)</td><td>Contig coverage</td><td>Contig N50</td></tr></table> | <table><tr><td>FuzzyPath</td><td>Illumina</td><td>CAST/Ei</td><td>200 bp</td><td>36</td><td>173 million</td><td>65×</td><td>76.03</td><td>80.0%</td><td>2,315</td></tr><tr><td>Velvet*</td><td>Illumina</td><td>CAST/Ei</td><td>200 bp</td><td>36</td><td>173 million</td><td>65×</td><td>58.09</td><td>61.15%</td><td>391</td><... |
d96747221a2485d5d421c8b072f553a410c94c5d8ca21a41113d00d22f5a88c5.png | complex | <table><tr><td rowspan="2"></td><td colspan="2">Infant HIV exposure category</td><td rowspan="2"><i>p</i>-Value<sup>b</sup></td></tr><tr><td>HEU (<i>N</i> = 60)</td><td>HUU (<i>N</i> = 72<sup>a</sup>)</td></tr><tr><td colspan="4">Maternal characteristics</td></tr><tr><td>Mean (SD) maternal age at enrollment</td><td>28.... | <table><tr><td rowspan="2"></td><td colspan="2">Infant HIV exposure category</td><td rowspan="2">p-Valueb</td></tr><tr><td>HEU (N = 60)</td><td>HUU (N = 72a)</td></tr><tr><td colspan="4">Maternal characteristics</td></tr><tr><td>Mean (SD) maternal age at enrollment</td><td>28.0 (5.1)</td><td>25.9 (6.2)</td><td>0.05</td... | <table><tr><td>Mean (SD) CD4 count (cells/mm3) at hospital discharge</td><td>563.9 (266.7)</td><td>–</td><td>–</td></tr><tr><td>Mean (SD) CD4% at hospital discharge</td><td>32.0 (9.4)</td><td>–</td><td>–</td></tr><tr><td>Mean (SD) viral load (log10 copies/mL) at hospital discharge</td><td>2.23 (0.81)</td><td>–</td><td>... |
a4ea613cc7faef2239f991b604f214940842d161c71c1a1012a9e7dba4c3ee44.png | simple | <table><tr><td>SOCIODEMOGRAPHIC AND CLINICAL CHARACTERISTICS</td><td>TREATMENT GROUP(N = 22)MEAN ± SD</td><td>WAITING LIST CONTROL GROUP (N = 24)MEAN ± SD</td><td>P</td></tr><tr><td>Age (years)</td><td>48.6 ± 11.2</td><td>53.0 ± 11.4</td><td>0.20</td></tr><tr><td>Sex (F/M)</td><td>15/7</td><td>20/4<... | <table><tr><td>SOCIODEMOGRAPHIC AND CLINICAL CHARACTERISTICS</td><td>TREATMENT GROUP(N = 22)MEAN ± SD</td><td>WAITING LIST CONTROL GROUP (N = 24)MEAN ± SD</td><td>P</td></tr></table> | <table><tr><td>Age (years)</td><td>48.6 ± 11.2</td><td>53.0 ± 11.4</td><td>0.20</td></tr><tr><td>Sex (F/M)</td><td>15/7</td><td>20/4</td><td>0.27</td></tr><tr><td>BMI (kg/m2)</td><td>24.9 ± 4.0</td><td>24.1 ± 3.1</td><td>0.47</td></tr><tr><td>Pain at rest (PR)</td><td>45.5 ± 20.9</td><td>42.3 ± 18.0</td><td>0.58</td></... |
c42a6d46fa87e0c776cf67d7f6b2c341fd9d9ee6fa52bebba08805c0badd578d.png | complex | <table><tr><td></td><td></td><td colspan="3">Formal only (n = 88)</td><td colspan="3">Formal and informal (n = 377)</td><td colspan="3">Informal only (n = 201)</td><td colspan="3">No help (n = 944)</td><td></td><td></td></tr><tr><td></td><td>N</td><td>n</td><td>%</td><td>(95% CI)</td><td>n</td><td>%</td><td>(95% CI)</t... | <table><tr><td></td><td></td><td colspan="3">Formal only (n = 88)</td><td colspan="3">Formal and informal (n = 377)</td><td colspan="3">Informal only (n = 201)</td><td colspan="3">No help (n = 944)</td><td></td><td></td></tr><tr><td></td><td>N</td><td>n</td><td>%</td><td>(95% CI)</td><td>n</td><td>%</td><td>(95% CI)</t... | <table><tr><td></td><td></td><td colspan="3">Formal only (n = 88)</td><td colspan="3">Formal and informal (n = 377)</td><td colspan="3">Informal only (n = 201)</td><td colspan="3">No help (n = 944)</td></tr><tr><td></td><td>N</td><td>n</td><td>%</td><td>(95% CI)</td><td>n</td><td>%</td><td>(95% CI)</td><td>n</td><td>%<... |
26133077f83620aec1430879ceac6c0e73a3566982e4c83b78e7b53e1d2047e0.png | complex | <table><tr><td>Patient no. (with cartilage damage)</td><td colspan="2">Teres ligament</td><td colspan="2">Joint capsule</td></tr><tr><td> </td><td>S100</td><td>Substance P</td><td>S100</td><td>Substance P</td></tr><tr><td>1.</td><td>+</td><td>+</td><td>-</td><td>-</td></tr><tr><td>4.</td><td>-</td><td>+</td><td>+</td><... | <table><tr><td>Patient no. (with cartilage damage)</td><td colspan="2">Teres ligament</td><td colspan="2">Joint capsule</td></tr><tr><td></td><td>S100</td><td>Substance P</td><td>S100</td><td>Substance P</td></tr><tr><td>1.</td><td>+</td><td>+</td><td>-</td><td>-</td></tr><tr><td>4.</td><td>-</td><td>+</td><td>+</td><t... | <table><tr><td>Patient no. (with cartilage damage)</td><td colspan="2">Teres ligament</td><td colspan="2">Joint capsule</td></tr><tr><td></td><td>S100</td><td>Substance P</td><td>S100</td><td>Substance P</td></tr><tr><td>16.</td><td></td><td></td><td>+</td><td></td></tr><tr><td>17.</td><td>-</td><td>-</td><td>-</td><td... |
df8cce802700a57e4d40cf52185fc16c9aca73eeb5c8615eff2910b5dc82ce57.png | complex | <table><tr><td colspan="6">Extracted peatland drains</td></tr><tr><td>Linear validation dataset</td><td>Drain</td><td>No drain</td><td></td><td>Total</td><td>Producer accuracy</td></tr><tr><td>Drain</td><td>193</td><td>131</td><td></td><td>324</td><td>0.60</td></tr><tr><td>No drain</td><td>39</td><td>2637</td><td></td>... | <table><tr><td colspan="6">Extracted peatland drains</td></tr><tr><td>Linear validation dataset</td><td>Drain</td><td>No drain</td><td></td><td>Total</td><td>Producer accuracy</td></tr><tr><td>Drain</td><td>193</td><td>131</td><td></td><td>324</td><td>0.60</td></tr><tr><td>No drain</td><td>39</td><td>2637</td><td></td>... | <table><tr><td></td><td></td><td></td><td>2830</td><td></td><td></td></tr><tr><td>Total</td><td>232</td><td>2768</td><td></td><td>3000</td><td></td></tr><tr><td>User accuracy</td><td>0.83</td><td>0.95</td><td></td><td></td><td></td></tr><tr><td>Kappa statistic</td><td>0.66</td><td></td><td></td><td>OA</td><td>0.94</td>... |
850199692d122819e314b0c44a1ce564d3f34b909e532bb27dcafe8515ca25aa.png | complex | <table><tr><td>Genes</td><td>Identity</td><td>Major function</td></tr><tr><td colspan="3">Genes that promote neuronal integrity during aging</td></tr><tr><td><i>daf-16</i></td><td>FoxO transcription factor</td><td>Upregulation of stress resistance genes</td></tr><tr><td><i>hsf-1</i></td><td>Heat shock transcription fac... | <table><tr><td>Genes</td><td>Identity</td><td>Major function</td></tr><tr><td colspan="3">Genes that promote neuronal integrity during aging</td></tr><tr><td>daf-16</td><td>FoxO transcription factor</td><td>Upregulation of stress resistance genes</td></tr><tr><td>hsf-1</td><td>Heat shock transcription factor</td><td>Up... | <table><tr><td>mec-9</td><td>EGF and Kunitz domain-containing ECM protein</td><td>Mechanosensory transduction, nerve attachment</td></tr><tr><td>mec-10</td><td>DEG/ENaC family sodium channel</td><td>Mechanosensory transduction</td></tr><tr><td>mec-12</td><td>α-tubulin</td><td>Mechanosensory transduction, axon transport... |
c6d55887588146f3974e371052a04e287ae4c5503456e3f03aa5d7ba8b20e88a.png | simple | <table><tr><td>Ribosomal protein gene</td><td>Chromosomal assignment in <i>C. elegans</i></td><td>Number of 5' codons omitted from analysis</td><td>Coding nucleotides used for analysis</td></tr><tr><td><i>rpl-1</i></td><td>III</td><td>3</td><td>642</td></tr><tr><td><i>rpl-2</i></td><td>V</td><td>0</td><td>783</td></tr>... | <table><tr><td>Ribosomal protein gene</td><td>Chromosomal assignment in C. elegans</td><td>Number of 5' codons omitted from analysis</td><td>Coding nucleotides used for analysis</td></tr><tr><td>rpl-1</td><td>III</td><td>3</td><td>642</td></tr><tr><td>rpl-2</td><td>V</td><td>0</td><td>783</td></tr><tr><td>rpl-10</td><t... | <table><tr><td>Ribosomal protein gene</td><td>Chromosomal assignment in C. elegans</td><td>Number of 5' codons omitted from analysis</td><td>Coding nucleotides used for analysis</td></tr><tr><td>rps-21</td><td>III</td><td>0</td><td>267</td></tr><tr><td>rps-24</td><td>IV</td><td>0</td><td>396</td></tr><tr><td>rps-25</td... |
22981e8a58d212641e3bb7a9398229d837cb4be4dd3b57b9e3797877b4f41de5.png | simple | <table><tr><td>Primary antibody</td><td>Manufacturer</td><td>Cat. number</td><td>Dilution</td><td>Source</td></tr><tr><td>OCT4</td><td>Abcam</td><td>ab18976</td><td>1/250</td><td>Rabbit</td></tr><tr><td>NANOG</td><td>Abcam</td><td>ab21624</td><td>1/100</td><td>Rabbit</td></tr><tr><td>SSEA4</td><td>Abcam</td><td>ab16287... | <table><tr><td>Primary antibody</td><td>Manufacturer</td><td>Cat. number</td><td>Dilution</td><td>Source</td></tr><tr><td>OCT4</td><td>Abcam</td><td>ab18976</td><td>1/250</td><td>Rabbit</td></tr><tr><td>NANOG</td><td>Abcam</td><td>ab21624</td><td>1/100</td><td>Rabbit</td></tr><tr><td>SSEA4</td><td>Abcam</td><td>ab16287... | <table><tr><td>Rhodopsin</td><td>Abcam</td><td>ab3267</td><td>1/200</td><td>Mouse</td></tr><tr><td>S opsin</td><td>Gift from Dr. Jeremy Nathans</td><td>/</td><td>1/5000</td><td>Rabbit</td></tr><tr><td>L/M opsin</td><td>Gift from Dr. Jeremy Nathans</td><td>/</td><td>1/5000</td><td>Rabbit</td></tr><tr><td>Recoverin</td><... |
605d9ca7ecbab031e591ecfdd3ee2ffcba223283200ff0549003d9c1f81c009a.png | simple | <table><tr><td> </td><td>Males N (%)</td><td>Females N (%)</td><td>Age in years median (Range)</td></tr><tr><td>Balochistan</td><td>52 (55%)</td><td>42 (45%)</td><td>29 (4 to 70)</td></tr><tr><td>Islamabad</td><td>62 (72%)</td><td>23 (28%)</td><td>26 (3 to 75)</td></tr><tr><td>KPK</td><td>231 (63%)</td><td>133 (37%)</t... | <table><tr><td></td><td>Males N (%)</td><td>Females N (%)</td><td>Age in years median (Range)</td></tr><tr><td>Balochistan</td><td>52 (55%)</td><td>42 (45%)</td><td>29 (4 to 70)</td></tr><tr><td>Islamabad</td><td>62 (72%)</td><td>23 (28%)</td><td>26 (3 to 75)</td></tr><tr><td>KPK</td><td>231 (63%)</td><td>133 (37%)</td... | <table><tr><td></td><td>Males N (%)</td><td>Females N (%)</td><td>Age in years median (Range)</td></tr><tr><td>Sindh</td><td>38 (62%)</td><td>23 (38%)</td><td>28 (0.3 to 65)</td></tr></table> |
04f10f9ea4c368848673cb4ca003d2d9ebd5cf807ed5c0460b278f9a46953679.png | simple | <table><tr><td>Task</td><td>Satisfactory</td><td>Unsatisfactory</td></tr><tr><td>(1) Performs a “time-out” and places monitors on patient (pulse oximetry and NIBP).</td><td>—</td><td>—</td></tr><tr><td>(2) Verifies that spinal kit tray, nonsterile and sterile gloves (correct size), and cleansing... | <table><tr><td>Task</td><td>Satisfactory</td></tr><tr><td>(1) Performs a “time-out” and places monitors on patient (pulse oximetry and NIBP).</td><td>—</td></tr><tr><td>(2) Verifies that spinal kit tray, nonsterile and sterile gloves (correct size), and cleansing solution are present.</td><td>—</td></tr><tr><td>(3) Pal... | <table><tr><td>Unsatisfactory</td></tr><tr><td>—</td></tr><tr><td>—</td></tr><tr><td>—</td></tr><tr><td>—</td></tr><tr><td>—</td></tr><tr><td>—</td></tr><tr><td>—</td></tr><tr><td>—</td></tr><tr><td>—</td></tr><tr><td>—</td></tr><tr><td>—</td></tr><tr><td>—</td></tr><tr><td>—</td></tr><tr><td>—</td></tr><tr><td>—</td><... |
dd26bb11da1ba9c877a6035d44541a1861c21a8567461c9e9184bf968c9ee64f.png | complex | <table><tr><td></td><td></td><td>KEGG pathway</td><td>Count</td><td>P value</td></tr><tr><td rowspan="3">HFF1_24 h vs HFF1</td><td rowspan="3">Up-regulated gene</td><td>hsa04622: RIG-I-like receptor signaling pathway</td><td>6</td><td>9.35E-05</td></tr><tr><td>hsa04620: Toll-like receptor signaling pathway</td><td>5</t... | <table><tr><td></td><td></td><td>KEGG pathway</td><td>Count</td><td>P value</td></tr><tr><td rowspan="3">HFF1_24 h vs HFF1</td><td rowspan="3">Up-regulated gene</td><td>hsa04622: RIG-I-like receptor signaling pathway</td><td>6</td><td>9.35E-05</td></tr><tr><td>hsa04620: Toll-like receptor signaling pathway</td><td>5</t... | <table><tr><td rowspan="4">HFF1_72 h vs HFF1</td><td>Up-regulated gene</td><td>hsa00250: Alanine, aspartate and glutamate metabolism</td><td>4</td><td>0.0349</td></tr><tr><td rowspan="3">Down-regulated gene</td><td>hsa04510: Focal adhesion</td><td>13</td><td>4.57E-05</td></tr><tr><td>hsa04810: Regulation of actin cytos... |
95ef2f5067c76827066ac860bed65e56562bd2ee9c5e10944aef3416bd253def.png | simple | <table><tr><td>Indicator</td><td>0 mg/L</td><td>1 mg/L</td><td>5 mg/L</td><td>10 mg/L</td><td>20 mg/L</td><td>40 mg/L</td><td>80 mg/L</td></tr><tr><td>Spontaneous movements of 36 hpf (bends/30 seconds)</td><td>11.17 ± 2.32</td><td>9.50 ± 1.52</td><td>10.17 ± 1.47</td><td> 8.17 ± 2.79<sup><i>∗&... | <table><tr><td>Indicator</td><td>0 mg/L</td><td>1 mg/L</td><td>5 mg/L</td><td>10 mg/L</td><td>20 mg/L</td><td>40 mg/L</td><td>80 mg/L</td></tr><tr><td>Spontaneous movements of 36 hpf (bends/30 seconds)</td><td>11.17 ± 2.32</td><td>9.50 ± 1.52</td><td>10.17 ± 1.47</td><td>8.17 ± 2.79∗∗</td><td>6.83 ± 1.94∗∗</td><td>7.83... | <table><tr><td>Area of pericardial edema (×104 μm2)</td><td>2.48 ± 0.53</td><td>2.60 ± 0.65</td><td>2.97 ± 0.32</td><td>4.05 ± 0.67∗∗</td><td>5.43 ± 0.64∗∗</td><td>5.50 ± 0.97∗∗</td><td>5.55 ± 0.75∗∗</td></tr><tr><td>Area of sac-yolk edema (×105 μm2)</td><td>2.44 ± 0.10</td><td>2.56 ± 0.10</td><td>2.42 ± 0.22</td><td>2... |
072fa098484d6961bdeec74ff090eeddd16337b29be805ea8cad7de2e7b48b26.png | simple | <table><tr><td>Author (reference number)</td><td>Gender</td><td>GA (wks)</td><td>Clinical features of LCH involvement</td><td>Outcome (survival)</td></tr><tr><td>Vade et al. [10]</td><td>F</td><td>35</td><td>Skin, hepatosplenomegaly, pulmonary failure</td><td>Died (9 days)</td></tr><tr><td>Gee et al. [11]</td><td>M</td... | <table><tr><td>Author (reference number)</td><td>Gender</td><td>GA (wks)</td><td>Clinical features of LCH involvement</td><td>Outcome (survival)</td></tr><tr><td>Vade et al. [10]</td><td>F</td><td>35</td><td>Skin, hepatosplenomegaly, pulmonary failure</td><td>Died (9 days)</td></tr><tr><td>Gee et al. [11]</td><td>M</td... | <table><tr><td>et al. [8]</td><td></td><td>36</td><td>ilure</td><td>(12 days)</td></tr><tr><td>Cheng et al. [9]</td><td>M</td><td>33</td><td>Hydrops fetalis, skin, pleural effusion</td><td>Died (36 hrs)</td></tr><tr><td>Herbrüggen et al. [13]</td><td>M</td><td>35</td><td>Skin, at 3 months, pulmonary and thymic mass</t... |
9aa8cdd069e78620526d8b7565ae1a67eb1a46730636b5c849d3e2411d425f48.png | complex | <table><tr><td></td><td colspan="2">Ontology 8a – Regex</td><td colspan="2">Ontology 7b – Voting</td></tr><tr><td>Total number of top-level terms</td><td>662</td><td></td><td>1886</td><td></td></tr><tr><td>Number of sampled top-level terms</td><td>200</td><td>30.2% of total</td><td>200</td><td>10.6% of tota... | <table><tr><td></td><td>Ontology 8a – Regex</td></tr><tr><td>Total number of top-level terms</td><td>662</td></tr><tr><td>Number of sampled top-level terms</td><td>200</td></tr><tr><td>Number of sampled top-level terms relevant to animal behaviour</td><td>84</td></tr><tr><td>Proportionate number of top- level animal be... | <table><tr><td>Ontology 8a – Regex</td><td colspan="2">Ontology 7b – Voting</td></tr><tr><td></td><td>1886</td><td></td></tr><tr><td>30.2% of total</td><td>200</td><td>10.6% of total</td></tr><tr><td>42% of sample</td><td>82</td><td>41% of sample</td></tr><tr><td></td><td>773</td><td></td></tr><tr><td>22% of sample</td... |
efc8d3866abf9e379be9716f0a721a1430c5edc5c4ae88b220aa8b1ec814605b.png | complex | <table><tr><td>Parameters</td><td colspan="3">Group</td></tr><tr><td> </td><td>Control diet</td><td>5% CL diet</td><td>10% CL diet</td></tr><tr><td>Food Intake (g/day)</td><td>2.25 ± 0.01</td><td>2.22 ± 0.04</td><td>2.24 ± 0.03</td></tr><tr><td>Initial body weight (g)</td><td>13.9 ± 0.32</td><td>13.... | <table><tr><td>Parameters</td><td colspan="3">Group</td></tr><tr><td></td><td>Control diet</td><td>5% CL diet</td><td>10% CL diet</td></tr><tr><td>Food Intake (g/day)</td><td>2.25 ± 0.01</td><td>2.22 ± 0.04</td><td>2.24 ± 0.03</td></tr><tr><td>Initial body weight (g)</td><td>13.9 ± 0.32</td><td>13.7 ± 0.27</td><td>13.7... | <table><tr><td>Parameters</td><td colspan="3">Group</td></tr><tr><td></td><td>Control diet</td><td>5% CL diet</td><td>10% CL diet</td></tr><tr><td>in (ng/mL)</td><td>.23</td><td>0.18</td><td>1.79 ± 0.31</td></tr><tr><td>Adiponectin (ng/mL)</td><td>3.58 ± 0.11</td><td>3.51 ± 0.15</td><td>3.30 ± 0.13</td></tr></table> |
5ac92705479f08eeaae67b2eef317ee38fc12ca99e28aeda058446f3d6eebb21.png | simple | <table><tr><td>Variable</td><td>LBC (M, SD) (<i>n =</i> 1031)</td><td>NLBC (M, SD) (<i>n =</i> 992)</td><td><i>t</i></td><td><i>p</i></td></tr><tr><td>Total</td><td>20.98, 6.273</td><td>21.66, 5.877</td><td>2.498</td><td>0.013</td></tr><tr><td>Gender</td><td></td><td></td><td></td><td></td></tr><tr><td>Male</td><td>20.... | <table><tr><td>Variable</td><td>LBC (M, SD) (n = 1031)</td><td>NLBC (M, SD) (n = 992)</td><td>t</td><td>p</td></tr><tr><td>Total</td><td>20.98, 6.273</td><td>21.66, 5.877</td><td>2.498</td><td>0.013</td></tr><tr><td>Gender</td><td></td><td></td><td></td><td></td></tr><tr><td>Male</td><td>20.99, 6.313</td><td>21.56, 5.9... | <table><tr><td>Variable</td><td>LBC (M, SD) (n = 1031)</td><td>NLBC (M, SD) (n = 992)</td><td>t</td><td>p</td></tr><tr><td>Female</td><td>21.05, 6.264</td><td>21.79, 5.772</td><td>1.910</td><td>0.056</td></tr><tr><td>Grade</td><td></td><td></td><td></td><td></td></tr><tr><td>Grade 4</td><td>22.14, 5.623</td><td>22.75, ... |
f4a940e7e9d384944e163f32494f62dcf580973dfab7bd8e51159e67e0664da8.png | complex | <table><tr><td rowspan="2">Variables</td><td>ALL N=383</td><td>Right hemiparesis 208 (54%)</td><td>Left hemiparesis 157 (41%)</td><td>Bilateral hemipareses 18 (5%)</td><td><i>P</i>-Value</td></tr><tr><td colspan="3">mean±SD, n (%)</td></tr><tr><td>Age in years</td><td>54.9±15.3</td><td>58.8±16.4</td><td>... | <table><tr><td rowspan="2">Variables</td><td>ALL N=383</td><td>Right hemiparesis 208 (54%)</td><td>Left hemiparesis 157 (41%)</td><td>Bilateral hemipareses 18 (5%)</td><td>P-Value</td></tr><tr><td colspan="3">mean±SD, n (%)</td><td colspan="2"></td></tr><tr><td>Age in years</td><td>54.9±15.3</td><td>58.8±16.4</td><td>5... | <table><tr><td rowspan="2">Variables</td><td>ALL N=383</td><td>Right hemiparesis 208 (54%)</td><td>Left hemiparesis 157 (41%)</td><td>Bilateral hemipareses 18 (5%)</td><td>P-Value</td></tr><tr><td colspan="3">mean±SD, n (%)</td><td colspan="2"></td></tr><tr><td>Home</td><td>374(98)</td><td>204(98)</td><td>153(98)</td><... |
78ff684168e62d338eebbf7e887a49dff1b1ecfab6626b8620f61c7b82b872c3.png | simple | <table><tr><td><i>P</i>-Value3</td><td><i>P</i>-Value2</td><td>Control Group</td><td><i>P</i>- Value1</td><td>After Treatment</td><td>Before Treatment</td><td></td></tr><tr><td>0.042**</td><td>0.002*</td><td>72.4±28.4</td><td>0.021*</td><td>58.02±15.33</td><td>51.06±17.77</td><td>TNF-α</td></tr><tr>... | <table><tr><td>P-Value3</td><td>P-Value2</td><td>Control Group</td><td>P- Value1</td><td>After Treatment</td><td>Before Treatment</td><td></td></tr><tr><td>0.042**</td><td>0.002*</td><td>72.4±28.4</td><td>0.021*</td><td>58.02±15.33</td><td>51.06±17.77</td><td>TNF-α</td></tr><tr><td>0.07*</td><td>0.</td><td></td><td>0.0... | <table><tr><td>P-Value3</td><td>P-Value2</td><td>Control Group</td><td>P- Value1</td><td>After Treatment</td><td>Before Treatment</td><td></td></tr><tr><td>*</td><td>002*</td><td>97.54±66.04</td><td>56*</td><td>31</td><td>54.66±31.50</td><td>L-1α</td></tr></table> |
98baf6ac94a430cef1da20df32dc5c98af547b9c137674d4968ab35fdf87bff1.png | complex | <table><tr><td rowspan="2" colspan="2">Test Condition</td><td colspan="4">Filter Medium</td></tr><tr><td>System A</td><td>System B</td><td>System C</td><td>System D</td></tr><tr><td>HLR (m<sup>3</sup>/m<sup>2</sup>/d)</td><td>Inflow (mg/L)</td><td>170.7 ± 61.4</td><td>170.7 ± 61.4</td><td>203.2 ± 51.5</t... | <table><tr><td colspan="2">Test Condition</td><td colspan="4">Filter Medium</td></tr></table> | <table><tr><td colspan="2">Test Condition</td><td>System A</td><td>System B</td><td>System C</td><td>System D</td></tr><tr><td>HLR (m3/m2/d)</td><td>Inflow (mg/L)</td><td>170.7 ± 61.4</td><td>170.7 ± 61.4</td><td>203.2 ± 51.5</td><td>203.2 ± 51.5</td></tr><tr><td rowspan="2">0.5</td><td>Outflow (mg/L)</td><td>36.5 ± 9.... |
ba6da193bc93d80daae9066898589d5a20f8ffde24368bbfc7357b8a98816a5a.png | complex | <table><tr><td rowspan="3"></td><td>Super-obese group</td><td>Comparison</td><td rowspan="3">OR</td><td rowspan="3">AOR<sup>b</sup></td></tr><tr><td>(<i>N</i> = 370)</td><td>(<i>N</i> = 621)</td></tr><tr><td>%</td><td>%</td></tr><tr><td colspan="5">Complications during pregnancy</td></tr><tr><td> Medical problems durin... | <table><tr><td rowspan="3"></td><td>Super-obese group</td><td>Comparison</td><td rowspan="3">OR</td><td rowspan="3">AORb</td></tr><tr><td>(N = 370)</td><td>(N = 621)</td></tr><tr><td>%</td><td>%</td></tr><tr><td colspan="5">Complications during pregnancy</td></tr><tr><td>Me</td><td></td><td>13</td><td>3.35 (2.43–4.62</... | <table><tr><td rowspan="3"></td><td>Super-obese group</td><td>Comparison</td><td rowspan="3">OR</td><td rowspan="3">AORb</td></tr><tr><td>(N = 370)</td><td>(N = 621)</td></tr><tr><td>%</td><td>%</td></tr><tr><td>dical problems during pregnancy</td><td>33.3</td><td></td><td>)</td><td> (2.64–4.11)</td></tr><tr><td>Obstet... |
75e6267aa200cdbd6402da92dcb5c9f2e40363f63c13c293ab6da7762b8d3ae9.png | simple | <table><tr><td>Composites</td><td>Relatives items</td></tr><tr><td>Parental sensitivity</td><td>Acknowledging; imitating; elaborating; parent gaze; positive affect; vocal appropriateness, clarity; appropriate range of affect; resourcefulness; praising; affectionate touch; supportive presence; infant led interaction</td... | <table><tr><td>Composites</td><td>Relatives items</td></tr><tr><td>Parental sensitivity</td><td>Acknowledging; imitating; elaborating; parent gaze; positive affect; vocal appropriateness, clarity; appropriate range of affect; resourcefulness; praising; affectionate touch; supportive presence; infant led interaction</td... | <table><tr><td>Composites</td><td>Relatives items</td></tr><tr><td>Child engagement</td><td>Joint attention; child positive affect; affection to parent; alertness; fatigue; vocalizations, verbal output; initiation; competent use of the environment; creative-symbolic play; infant-led interaction</td></tr><tr><td>Dyadic ... |
a50e721275aae76d4e8d370d422a0b596980d401e6aa93cdf8cf245c9af3188e.png | complex | <table><tr><td colspan="3">PRISMA statement results</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td colspan="2">Yes</td><td colspan="2">Partial</td><td colspan="2">No</td></tr><tr><td>Title</td><td>1</td><td>Title</td><td>221</td><td>(93%)</td><td>13</td><td>(5%)</td><t... | <table><tr><td colspan="3">PRISMA statement results</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td colspan="2">Yes</td><td colspan="2">Partial</td><td colspan="2">No</td></tr><tr><td>Title</td><td>1</td><td>Title</td><td>221</td><td>(93%)</td><td>13</td><td>(5%)</td><t... | <table><tr><td></td><td>8</td><td>arch</td><td></td><td>)</td><td></td><td></td><td></td><td>%)</td></tr><tr><td></td><td>9</td><td>Study selection</td><td>134</td><td>(57%)</td><td>30</td><td>(13%)</td><td>72</td><td>(30%)</td></tr><tr><td></td><td>10</td><td>Data collection process</td><td>149</td><td>(63%)</td><td>1... |
d70ab01a7cee882fa47791016870a64d2797a2c33e28deca99c7971896196a07.png | simple | <table><tr><td>Patients with total lipid profile</td><td>CVD + DM (n = 753)</td><td>CVD (w/o DM) (n = 280)</td><td>DM (w/o CVD) (n = 586)</td><td>SCORE ≥ 10% (n = 30)</td></tr><tr><td>LDL-C ≥ 1.8 mmol/L and LDL-reduction <50% [%]</td><td>74.4</td><td>63.9</td><td>65.4</td><td>80.0</td></tr><tr><td>Low HD... | <table><tr><td>Patients with total lipid profile</td><td>CVD + DM (n = 753)</td><td>CVD (w/o DM) (n = 280)</td><td>DM (w/o CVD) (n = 586)</td><td>SCORE ≥ 10% (n = 30)</td></tr><tr><td>LDL-C ≥ 1.8 mmol/L and LDL-reduction <50% [%]</td><td>74.4</td><td>63.9</td><td>65.4</td><td>80.0</td></tr><tr><td>Low HDL-C (<1.0 [men]... | <table><tr><td>Patients with total lipid profile</td><td>CVD + DM (n = 753)</td><td>CVD (w/o DM) (n = 280)</td><td>DM (w/o CVD) (n = 586)</td><td>SCORE ≥ 10% (n = 30)</td></tr><tr><td>All patients</td><td>(n = 829)</td><td>(n = 312)</td><td>(n = 629)</td><td>(n= 30)</td></tr><tr><td>LDL-C ≥ 1.8 mmol/L and LDL-reduction... |
468f1f07b1d5df8475c46466212a0c2d4eedd729d8738718589bdeecd42c5893.png | simple | <table><tr><td></td><td></td><td>NorthernTanna(n = 364)</td><td>Northern TannaHighlands(n = 515)</td><td>Southern Tanna(n = 370)</td><td>Aneityum(n = 517)</td><td>Total(n = 1766)</td></tr><tr><td></td><td>Male</td><td>47.3 (172)</td><td>48.1 (245)</td><td>50.3 (186)</td><td>48.6 (251)</td><td>48.5 (854)</td></tr><tr><t... | <table><tr><td></td><td></td><td>NorthernTanna(n = 364)</td><td>Northern TannaHighlands(n = 515)</td><td>Southern Tanna(n = 370)</td><td>Aneityum(n = 517)</td><td>Total(n = 1766)</td></tr><tr><td></td><td>Male</td><td>47.3 (172)</td><td>48.1 (245)</td><td>50.3 (186)</td><td>48.6 (251)</td><td>48.5 (854)</td></tr><tr><t... | <table><tr><td></td><td></td><td>NorthernTanna(n = 364)</td><td>Northern TannaHighlands(n = 515)</td><td>Southern Tanna(n = 370)</td><td>Aneityum(n = 517)</td><td>Total(n = 1766)</td></tr><tr><td></td><td>No</td><td>21.8 (79)</td><td>61.7 (269)</td><td>11.1 (41)</td><td>10.1 (52)</td><td>26.1 (441)</td></tr><tr><td>Use... |
c9d9ac59878865d43e3cadd8398563607ed6bbb23da627a884ff2c7944ce2e50.png | complex | <table><tr><td rowspan="2">Difference</td><td colspan="2">PSF + TOF vs. PSF</td><td colspan="2">3D-OSEM + TOF vs. 3D-OSEM</td></tr><tr><td>Low TBR</td><td>High TBR</td><td>Low TBR</td><td>High TBR</td></tr><tr><td></td><td>**</td><td>n.s.</td><td>**</td><td>n.s.</td></tr><tr><td>Median</td><td>10.4</td><td>1.8</td><td>... | <table><tr><td rowspan="2">Difference</td><td colspan="2">PSF + TOF vs. PSF</td><td colspan="2">3D-OSEM + TOF vs. 3D-OSEM</td></tr><tr><td>Low TBR</td><td>High TBR</td><td>Low TBR</td><td>High TBR</td></tr><tr><td></td><td>**</td><td>n.s.</td><td>**</td><td>n.s.</td></tr></table> | <table><tr><td>Median</td><td>10.4</td><td>1.8</td><td>8.6</td><td>−0.1</td></tr><tr><td>IQR</td><td>3.1 to 19.0</td><td>−0.8 to 5.5</td><td>3.3 to 14.8</td><td>−6.0 to 2.4</td></tr><tr><td>Range</td><td>1.0 to 27.2</td><td>−16.7 to 27.9</td><td>−5.9 to 17.5</td><td>−13.9 to 24.0</td></tr></table> |
d5ebc7bfdcc301dab5bfc94681a01d0054799d39eda700f93cef47b36f1192d4.png | simple | <table><tr><td>Cell line</td><td>Gq mutant</td><td>G11 mutant</td><td>BRAF mutant</td></tr><tr><td>Melanocytes</td><td>WT</td><td>WT</td><td>WT</td></tr><tr><td>OCM1</td><td>WT</td><td>WT</td><td>V600E</td></tr><tr><td>OCM3</td><td>WT</td><td>WT</td><td>V600E</td></tr><tr><td>OMM1</td><td>WT</td><td>Q209L</td><td>WT</t... | <table><tr><td>Cell line</td><td>Gq mutant</td><td>G11 mutant</td></tr><tr><td>Melanocytes</td><td>WT</td><td>WT</td></tr><tr><td>OCM1</td><td>WT</td><td>WT</td></tr><tr><td>OCM3</td><td>WT</td><td>WT</td></tr><tr><td>OMM1</td><td>WT</td><td>Q209L</td></tr><tr><td>OMM2.3*</td><td>Q209P</td><td>WT</td></tr><tr><td>Mel27... | <table><tr><td>BRAF mutant</td></tr><tr><td>WT</td></tr><tr><td>V600E</td></tr><tr><td>V600E</td></tr><tr><td>WT</td></tr><tr><td>WT</td></tr><tr><td>WT</td></tr><tr><td>V600E</td></tr><tr><td>V600E</td></tr><tr><td>V600E</td></tr><tr><td>V600E</td></tr><tr><td>V600E</td></tr><tr><td>V600E</td></tr><tr><td>V600E</td></... |
29da39f626a06e89d50b7395a1fb9dec5aae8157f4b3de97b96f23fac4d0d299.png | complex | <table><tr><td></td><td>Tolvaptan group</td><td>Conventional group</td><td><i>p</i> value</td></tr><tr><td>Number</td><td>26</td><td>180</td><td></td></tr><tr><td>Age (years)</td><td>75 ± 11</td><td>74 ± 12</td><td>0.88</td></tr><tr><td>Sex (male,%)</td><td>15 (58)</td><td>96 (53)</td><td>0.68</td></tr><tr><t... | <table><tr><td></td><td>Tolvaptan group</td><td>Conventional group</td><td>p value</td></tr><tr><td>Number</td><td>26</td><td>180</td><td></td></tr><tr><td>Age (year</td><td>75</td><td>7</td><td>0.88</td></tr></table> | <table><tr><td></td><td>Tolvaptan group</td><td>Conventional group</td><td>p value</td></tr><tr><td>s)</td><td> ± 11</td><td>4 ± 12</td><td></td></tr><tr><td>Sex (male,%)</td><td>15 (58)</td><td>96 (53)</td><td>0.68</td></tr><tr><td>BMI (kg/m2)</td><td>23.8 ± 4.4</td><td>23.6 ± 4.4</td><td>0.77</td></tr><tr><td>Previou... |
1b0dae4c6b613c953b63519367e222eda6b6746d130fc842a0d5873cfd6f60e7.png | complex | <table><tr><td colspan="2">Diagnosis</td><td>Diagnostic Clues</td></tr><tr><td colspan="2">Psoriasis</td><td>Usually involves extensor, palmar, plantar, nails and extensor areas. Thick plaques sharply limited with silvery white scales. Positive family history. Arthritis present in 10% of patients. Uncommon in children.... | <table><tr><td colspan="2">Diagnosis</td><td>Diagnostic Clues</td></tr><tr><td colspan="2">Psoriasis</td><td>Usually involves extensor, palmar, plantar, nails and extensor areas. Thick plaques sharply limited with silvery white scales. Positive family history. Arthritis present in 10% of patients. Uncommon in children.... | <table><tr><td colspan="2">cea</td><td>ith slight desquamation. Recurrent edema and flushing.</td></tr><tr><td colspan="2">Systemic Lupus Erythematous (SLE)</td><td>In acute stage, butterfly rash on face that spares the nose bridge or nasolabial folds. Photosensitivity is common. Skin lesions are generally associated w... |
03bdd2205dab4e85fd53bf0870b42acad2f2fc56b719ff04bd7a26be9cc7ada3.png | simple | <table><tr><td>Assembler</td><td>Type<sup>†</sup></td><td>Splits reads*</td><td>Author</td><td>Cost</td><td>Source available</td><td>URL</td></tr><tr><td>CAP3</td><td>OLC†</td><td>No</td><td>X Huang and A Madan [38]</td><td>Free for use at non-profit organizations</td><td>No</td><td>http://seq.cs.iastate.ed... | <table><tr><td>Assembler</td><td>Type†</td><td>Splits reads*</td><td>Author</td><td>Cost</td><td>Source available</td><td>URL</td></tr><tr><td>CAP3</td><td>OLC†</td><td>No</td><td>X Huang and A Madan [38]</td><td>Free for use at non-profit organizations</td><td>No</td><td>http://seq.cs.iastate.edu/</td></tr><tr><td>CLC... | <table><tr><td>MIRA 3.0</td><td>OLC</td><td>No</td><td>Bastien Chevreux [40]</td><td>Free</td><td>Yes, GPL</td><td>http://sourceforge.net/projects/mira-assembler/</td></tr><tr><td>Newbler 2.3 and Newbler 2.5</td><td>OLC</td><td>Yes</td><td>Roche 454 [37]</td><td>Free for academic use</td><td>No</td><td>http://454.com/p... |
cb54a0e31cbd93f8b1c945e924a4c3c8dff1d91668e2262b394bd411c643e9ce.png | simple | <table><tr><td>Trait</td><td><i>b</i><sub>( <i>P </i>, <i>DGV </i>)</sub></td><td><i>r</i><sub>( <i>DGV </i>, <i>P </i>)</sub></td><td>Accuracy</td></tr><tr><td>14:0</td><td>0.93</td><td>0.43</td><td>0.57</td></tr><tr><td>16:0</td><td>0.95</td><td>0.38</td><td>0.53</td></tr><tr><td>18:0</td><td>0.66</td><td>0.20</td><t... | <table><tr><td>Trait</td><td>b( P , DGV )</td></tr><tr><td>14:0</td><td>0.93</td></tr><tr><td>16:0</td><td>0.95</td></tr><tr><td>18:0</td><td>0.66</td></tr><tr><td>cis-9 18:1</td><td>0.77</td></tr><tr><td>cis-12 18:1</td><td>0.89</td></tr><tr><td>trans-12 18:1</td><td>0.03</td></tr><tr><td>18:3n3</td><td>0.13</td></tr>... | <table><tr><td>r( DGV , P )</td><td>Accuracy</td></tr><tr><td>0.43</td><td>0.57</td></tr><tr><td>0.38</td><td>0.53</td></tr><tr><td>0.20</td><td>0.27</td></tr><tr><td>0.26</td><td>0.35</td></tr><tr><td>0.18</td><td>0.35</td></tr><tr><td>0.01</td><td>0.03</td></tr><tr><td>0.01</td><td>0.03</td></tr><tr><td>0.06</td><td>... |
a2598b61e1bf04342679897a9c88ef0a6bc37fadb28af439bb7fb7e70013a82d.png | complex | <table><tr><td></td><td></td><td>MZ</td><td>DZ</td><td>Total no pairs</td></tr><tr><td rowspan="3">IBS</td><td>Concordant pairs</td><td>14</td><td>10</td><td>24</td></tr><tr><td>Discordant pairs</td><td>95</td><td>193</td><td>288</td></tr><tr><td>Probandwise concordance rate</td><td>0.23</td><td>0.09*</td><td></td></tr... | <table><tr><td></td><td></td><td>MZ</td><td>DZ</td><td>Total no pairs</td></tr><tr><td rowspan="3">IBS</td><td>Concordant pairs</td><td>14</td><td>10</td><td>24</td></tr><tr><td>Discordant pairs</td><td>95</td><td>193</td><td>288</td></tr><tr><td>Probandwise concordance rate</td><td>0.23</td><td>0.09*</td><td></td></tr... | <table><tr><td>Depression</td><td>Probandwise concordance rate</td><td>0.22</td><td>0.15*</td><td></td></tr><tr><td rowspan="3">Anxiety</td><td>Concordant pairs</td><td>56</td><td>55</td><td>111</td></tr><tr><td>Discordant pairs</td><td>186</td><td>422</td><td>608</td></tr><tr><td>Probandwise concordance rate</td><td>0... |
139d77f11bd39e31ff2279d7cc7432544d1a542d0278d7d21f3529ee1af22d09.png | complex | <table><tr><td> </td><td>Ashford <i>et al</i>.[46](MMSE)</td><td>Gibbons <i>et al</i>.[48]UK (MMSE)</td><td>Gibbons <i>et al.</i>[48]US (MMSE)</td><td>Mungas and Reed[1](BIMCT/MMSE)</td></tr><tr><td rowspan="2">Truncated above upper limit</td><td>Recall: tree</td><td>No ifs ands or buts</td><td rowspan="2"> </td><td ro... | <table><tr><td></td><td>Ashford et al.[46](MMSE)</td><td>Gibbons et al.[48]UK (MMSE)</td><td>Gibbons et al.[48]US (MMSE)</td><td>Mungas and Reed[1](BIMCT/MMSE)</td></tr></table> | <table><tr><td rowspan="2">Truncated above upper limit</td><td>Recall: tree</td><td>No ifs ands or buts</td><td rowspan="2"></td><td rowspan="2"></td></tr><tr><td>Recall: flag</td><td>Recall nouns</td></tr><tr><td rowspan="5">1st quartile (most difficult)</td><td>Serial sevens: subtraction 5</td><td>Orientation to date... |
ce858e91e6789702870f3719a49dba88b7f9f3788a6c10da8b334633ff2f2f3e.png | complex | <table><tr><td>Chr</td><td>GWAS QTL</td><td>Bi-parental counterpart</td><td>Bins</td><td>Marker associated with GLS resistance QTL</td><td>Source of variation<sup>a</sup></td><td>Minor allele frequency</td><td>Physical coordinate</td><td>SNP effects</td><td>Heritability of a SNP<sup>b</sup></td><td>Maximum heritability... | <table><tr><td>Chr</td><td>GWAS QTL</td><td>Bi-parental counterpart</td><td>Bins</td><td>Marker associated with GLS resistance QTL</td><td>Source of variationa</td><td>Minor allele frequency</td><td>Physical coordinate</td><td>SNP effects</td><td>Heritability of a SNPb</td><td>Maximum heritability of a chromosome</td><... | <table><tr><td>8</td><td rowspan="2">GLS 8.2</td><td rowspan="2">QTLGLSchr8a</td><td>8.02</td><td>PZE-108020413</td><td>[T/C]</td><td>0.48</td><td>19,550,800</td><td>0.00468907</td><td>0.000177343</td><td>0.000585845</td></tr><tr><td>8</td><td>8.02</td><td>PZE-108022710</td><td>[T/G]</td><td>0.43</td><td>21,753,432</td... |
a9a5f88d618fb06aebc274745c2c590b121c06ca30ca2811e6cf508230c370e8.png | simple | <table><tr><td>Definition</td><td>Grade</td><td>Ki-67%</td><td>Mitotic index</td></tr><tr><td>NET - neuroendocrine tumour, low grade</td><td>G1</td><td>≤2</td><td><2</td></tr><tr><td>NET - neuroendocrine tumour, intermediate grade</td><td>G2</td><td>3 to 20</td><td>2 to 20</td></tr><tr><td>NET - neuroendocrine... | <table><tr><td>Definition</td><td>Grade</td><td>Ki-67%</td><td>Mitotic index</td></tr></table> | <table><tr><td>NET - neuroendocrine tumour, low grade</td><td>G1</td><td>≤2</td><td><2</td></tr><tr><td>NET - neuroendocrine tumour, intermediate grade</td><td>G2</td><td>3 to 20</td><td>2 to 20</td></tr><tr><td>NET - neuroendocrine carcinoma, high grade</td><td>G3</td><td>>20</td><td>>20</td></tr></table> |
01c87d38848f661f633d7b0d55366e347455f002e2bd7ab97af6bddf995b11ab.png | complex | <table><tr><td></td><td colspan="2">Ectopic pregnancy<sup>a</sup></td><td colspan="2">Preterm delivery among live-born infants<sup>b</sup></td></tr><tr><td></td><td><i>n </i>(prevalence %)</td><td>Adjusted odds ratio (95% confidence interval)</td><td><i>n </i>(prevalence %)</td><td>Adjusted odds ratio (95% confidence i... | <table><tr><td></td><td colspan="2">Ectopic pregnancya</td><td colspan="2">Preterm delivery among live-born infantsb</td></tr><tr><td></td><td>n (prevalence %)</td><td>Adjusted odds ratio (95% confidence interval)</td><td>n (prevalence %)</td><td>Adjusted odds ratio (95% confidence interval)</td></tr><tr><td>Mother not... | <table><tr><td></td><td colspan="2">Ectopic pregnancya</td><td colspan="2">Preterm delivery among live-born infantsb</td></tr><tr><td></td><td>n (prevalence %)</td><td>Adjusted odds ratio (95% confidence interval)</td><td>n (prevalence %)</td><td>Adjusted odds ratio (95% confidence interval)</td></tr><tr><td>Pregnancy ... |
df61ecd24a6c7dcb04ddfb49db89770c1086f88b269e31f9b20e48357ccf5436.png | simple | <table><tr><td>Block 1 set</td><td>Block 2 set</td><td>Block 3set</td><td>Block 4 set</td><td>Block 5 set</td><td>Block 6 set</td><td>Block 7 set</td><td>Block 8 set</td></tr><tr><td>NT</td><td>NT</td><td>NT</td><td>NT</td><td>NT</td><td>NT</td><td>NT</td><td>NT</td></tr><tr><td>NT</td><td>NT</td><td>NT</td><td>NT</td>... | <table><tr><td>Block 1 set</td><td>Block 2 set</td><td>Block 3set</td><td>Block 4 set</td><td>Block 5 set</td><td>Block 6 set</td><td>Block 7 set</td><td>Block 8 set</td></tr><tr><td>NT</td><td>NT</td><td>NT</td><td>NT</td><td>NT</td><td>NT</td><td>NT</td><td>NT</td></tr><tr><td>NT</td><td>NT</td><td>NT</td><td>NT</td>... | <table><tr><td></td><td>T</td><td>T</td><td></td><td>NT</td><td></td><td>T</td><td>OG2</td></tr><tr><td>OG1</td><td>NT</td><td>NT</td><td>NT</td><td>NT</td><td>NT</td><td>NT</td><td>OG2</td></tr><tr><td>OG1</td><td>NT</td><td>T</td><td>T</td><td>T</td><td>T</td><td>NT</td><td>OG2</td></tr><tr><td>NT</td><td>NT</td><td>... |
894f0898d8fbe075d114ca40498977ed8095a69208b634eaa745284691cba930.png | simple | <table><tr><td>Institutions</td><td>Key informant interview</td><td>Group Interview</td><td>Focus Group Discussion</td></tr><tr><td>National Level</td><td> </td><td> </td><td> </td></tr><tr><td><i>MoH</i></td><td>10</td><td>0</td><td>0</td></tr><tr><td><i>PMU and CCM</i></td><td>6</td><td>0</td><td>1</td></tr><tr><td><... | <table><tr><td>Institutions</td><td>Key informant interview</td><td>Group Interview</td><td>Focus Group Discussion</td></tr><tr><td>National Level</td><td></td><td></td><td></td></tr><tr><td>MoH</td><td>10</td><td>0</td><td>0</td></tr><tr><td>PMU and CCM</td><td>6</td><td>0</td><td>1</td></tr><tr><td>WHO</td><td>3</td>... | <table><tr><td>Institutions</td><td>Key informant interview</td><td>Group Interview</td><td>Focus Group Discussion</td></tr><tr><td>AIS</td><td>1</td><td></td><td>0</td></tr><tr><td>CARE International</td><td>1</td><td>0</td><td>0</td></tr><tr><td>Districts and CHCs</td><td>8</td><td>5</td><td>6</td></tr><tr><td>Health... |
7d04e740f34fff82df1c9fcab582d43cc14969ad1e2936867ae777319d0b4fcd.png | complex | <table><tr><td></td><td></td><td colspan="3">Age at infection</td><td colspan="3">Serotype<sup>a</sup></td><td colspan="3">Serologic response<sup>b</sup></td><td colspan="3">Clinical category<sup>c</sup></td></tr><tr><td></td><td>Infection order</td><td>1</td><td>2</td><td>3</td><td>1</td><td>2</td><td>3</td><td>1</td>... | <table><tr><td></td><td></td><td colspan="2">Age at infection</td></tr><tr><td></td><td>Infection order</td><td>1</td><td>2</td></tr><tr><td>Indiv.</td><td>Titers > 10d</td><td></td><td></td></tr><tr><td>1</td><td>0</td><td>8.7</td><td>12.8</td></tr><tr><td>2</td><td>0</td><td>8.9</td><td>10.9</td></tr><tr><td>3</td><t... | <table><tr><td>Age at infection</td><td colspan="3">Serotypea</td><td colspan="3">Serologic responseb</td><td colspan="3">Clinical categoryc</td></tr><tr><td>3</td><td>1</td><td>2</td><td>3</td><td>1</td><td>2</td><td>3</td><td>1</td><td>2</td><td>3</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td... |
b1379060f093b13678d63225a2b26d0a31fabf0c748bbf8728040cb896e75305.png | complex | <table><tr><td>Targeted Viruses</td><td>Name</td><td>Sequence of Oligonucleotide (5'–3')</td><td>Location</td><td>Amplicon Length</td></tr><tr><td rowspan="3">Hepatitis A Virus</td><td>Forward primer</td><td>GGT AGG CTA CGG GTG AAA C</td><td>393~411 <sup>a</sup></td><td rowspan="3">116 nt</td></tr><tr><td>Reverse... | <table><tr><td>Targeted Viruses</td><td>Name</td><td>Sequence of Oligonucleotide (5'–3')</td><td>Location</td><td>Amplicon Length</td></tr><tr><td rowspan="3">Hepatitis A Virus</td><td>Forward primer</td><td>GGT AGG CTA CGG GTG AAA C</td><td>393~411 a</td><td rowspan="3">116 nt</td></tr><tr><td>Reverse primer</td><td>C... | <table><tr><td>Hepatitis E Virus</td><td>Probe</td><td>Cy5-TGA TTC TCA GCC CTT CGC-BHQ</td><td>5284~5301 b</td><td>70 nt</td></tr></table> |
cfda2b2544476c726d8d04779f2d882df05e22c964d48eaeb151c863be613a64.png | complex | <table><tr><td>Variables</td><td>Group I (%)</td><td>Group II (%)</td><td><i>p</i>-value</td></tr><tr><td>Mean cardiopulmonary bypass time (minutes)</td><td>104 ± 41</td><td>98 ± 53</td><td>0.34</td></tr><tr><td>Mean aortic cross-clamping time (minutes)</td><td>82 ± 32</td><td>78 ± 37</td><td>0.41</... | <table><tr><td>Variables</td><td>Group I (%)</td><td>Group II (%)</td><td>p-value</td></tr><tr><td>Mean cardiopulmonary bypass time (minutes)</td><td>104 ± 41</td><td>98 ± 53</td><td>0.34</td></tr><tr><td>Mean aortic cross-clamping time (minutes)</td><td>82 ± 32</td><td>78 ± 37</td><td>0.41</td></tr><tr><td>Annulus enl... | <table><tr><td>Variables</td><td>Group I (%)</td><td>Group II (%)</td><td>p-value</td></tr><tr><td>Intestinal infarction</td><td>1 (0.4 %)</td><td>0</td><td>1.0</td></tr><tr><td>Multi organ failure</td><td>3 (1.1 %)</td><td>1 (1.7 %)</td><td>1.0</td></tr><tr><td>Aortic dissection</td><td>1(0.4 %)</td><td>0</td><td>1.0<... |
8b59e710408f8e698a7a2bd422725d0ed83efb2ae9d8928562c546929d214065.png | complex | <table><tr><td>SDQ Variables</td><td>CBCL Variables</td><td>r<sub>s</sub></td><td>p-value</td></tr><tr><td rowspan="6">Emotional symptoms</td><td>Anxiety/depression</td><td>0.480</td><td>0.002</td></tr><tr><td>Total internalizing problems</td><td>0.503</td><td>0.001</td></tr><tr><td>Attention/hyperactivity</td><td>0.41... | <table><tr><td>SDQ Variables</td><td>CBCL Variables</td><td>rs</td><td>p-value</td></tr><tr><td rowspan="6">Emotional symptoms</td><td>Anxiety/depression</td><td>0.480</td><td>0.002</td></tr><tr><td>Total internalizing problems</td><td>0.503</td><td>0.001</td></tr><tr><td>Attention/hyperactivity</td><td>0.412</td><td>0... | <table><tr><td rowspan="3">nduct problems</td><td>lizing problems</td><td>675</td><td>0.001</td></tr><tr><td>Stress problem</td><td>0.637</td><td><0.001</td></tr><tr><td>Total of EB problems</td><td>0.664</td><td><0.001</td></tr><tr><td rowspan="3">Hyperactivity problem</td><td>Attention/hyperactivity</td><td>0.586</td... |
624370a548427f892b708e0957a4b2178c020a26235c670f7d2c6d8578c541d7.png | complex | <table><tr><td rowspan="2">Clinicopathological parameters</td><td rowspan="2"><i>n</i><sup>a</sup></td><td colspan="2">ENAH expression</td><td rowspan="2">χ<sup>2</sup></td><td rowspan="2"><i>P</i> value</td></tr><tr><td>High</td><td>Low</td></tr><tr><td>All</td><td>238</td><td>136</td><td>102</td><td></td><td></t... | <table><tr><td rowspan="2">Clinicopathological parameters</td><td rowspan="2">na</td><td colspan="2">ENAH expression</td><td rowspan="2">χ2</td><td rowspan="2">P value</td></tr><tr><td>High</td><td>Low</td></tr><tr><td>All</td><td>238</td><td>136</td><td>102</td><td></td><td></td></tr><tr><td>Age (years)</td><td></td><... | <table><tr><td>N0</td><td>84</td><td>36</td><td>48</td><td></td><td></td></tr><tr><td>N1</td><td>44</td><td>23</td><td>21</td><td></td><td></td></tr><tr><td>N2</td><td>37</td><td>23</td><td>14</td><td></td><td></td></tr><tr><td>N3</td><td>73</td><td>54</td><td>19</td><td></td><td></td></tr><tr><td>Distant metastasis</t... |
36982b2e904dcb977e86b856b576311a00648f3b8b1abbff14fb0552ea62ffb3.png | simple | <table><tr><td>Domains</td><td>Amino acid Positions</td></tr><tr><td>PWWP1</td><td>323–388</td></tr><tr><td>NLS1</td><td>512–529</td></tr><tr><td>NLS2</td><td>1157–1174</td></tr><tr><td>NLS3</td><td>1471–1488</td></tr><tr><td>PHD1</td><td>1543–1589</td></tr><tr><td>PHD2</td><td>1590–... | <table><tr><td>Domains</td><td>Amino acid Positions</td></tr><tr><td>PWWP1</td><td>323–388</td></tr><tr><td></td><td></td></tr></table> | <table><tr><td>Domains</td><td>Amino acid Positions</td></tr><tr><td>NLS1</td><td>512–529</td></tr><tr><td>NLS2</td><td>1157–1174</td></tr><tr><td>NLS3</td><td>1471–1488</td></tr><tr><td>PHD1</td><td>1543–1589</td></tr><tr><td>PHD2</td><td>1590–1639</td></tr><tr><td>PHD3</td><td>1640–1693</td></tr><tr><td>PHD4</td><td>... |
701c4577bccdebbb1cd2824bbac79fe4a8af8ca0da0a496f92dcb4bfe05bf46a.png | complex | <table><tr><td> </td><td colspan="4">Intervention departments</td><td colspan="4">Control departments</td><td>Significance tests</td></tr><tr><td> </td><td colspan="2">Baseline</td><td colspan="2">Follow-up</td><td colspan="2">Baseline</td><td colspan="2">Follow-up</td><td>Group x Time</td></tr><tr><td> </td><td colspa... | <table><tr><td></td><td colspan="4">Intervention departments</td><td colspan="4">Control departments</td><td>Significance tests</td></tr><tr><td></td><td colspan="2">Baseline</td><td colspan="2">Follow-up</td><td colspan="2">Baseline</td><td colspan="2">Follow-up</td><td>Group x Time</td></tr><tr><td></td><td colspan="... | <table><tr><td>Indicators of patient care quality</td><td>M</td><td>SD</td><td>M</td><td>SD</td><td>M</td><td>SD</td><td>M</td><td>SD</td><td>F(df = 1); p</td></tr><tr><td>1 Organization of physicians’ care</td><td>4.20</td><td>.82</td><td>4.23</td><td>.75</td><td>4.13</td><td>.76</td><td>4.01</td><td>.84</td><td>3.67;... |
c8b2b6b544def33064a251b97c6a231e446e5866f4daee6521b24f9c56a61239.png | complex | <table><tr><td colspan="2">AEROBIC</td></tr><tr><td>Frequency:</td><td>20-60 min/day - 3-5 days/week</td></tr><tr><td>Intensity:</td><td>Light (< 40% HRR or VO2R); Moderate (40-60% HRR or VO2R); Hard (> 60% HRR or VO2R)</td></tr><tr><td>Type:</td><td>Walk or Cicle</td></tr><tr><td colspan="2">RESISTANCE</td></tr>... | <table><tr><td colspan="2">AEROBIC</td></tr><tr><td>Frequency:</td><td>20-60 min/day - 3-5 days/week</td></tr><tr><td>Intensity:</td><td>Light (< 40% HRR or VO2R); Moderate (40-60% HRR or VO2R); Hard (> 60% HRR or VO2R)</td></tr><tr><td>Type:</td><td>Walk or Cicle</td></tr></table> | <table><tr><td colspan="2">AEROBIC</td></tr><tr><td colspan="2">RESISTANCE</td></tr><tr><td>Frequency:</td><td>2-3x/week</td></tr><tr><td>Intensity:</td><td>Light (40-50% 1MR); Moderate (60-80% 1MR); Hard (>80% 1MR)</td></tr><tr><td>Type:</td><td>Progressive (2-4 sets; 8-15 reps; Large Muscle Groups)</td></tr><tr><td c... |
eab68463a0b5f05b867436882e529c5055e8d4a647e9e236f2d2b4a68e78beeb.png | complex | <table><tr><td> Groups</td><td colspan="2">Lung</td><td colspan="2">Lymph node</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> </td><td> </td><td> </td><td> </td><td> </td><td>Liver</td><td>Spleen</td><td>Kidney</td><td>Stomach</td><td>Intestine</td><td>Heart</td></tr><tr><td> </td><td>++*... | <table><tr><td>Groups</td></tr><tr><td></td></tr><tr><td></td></tr><tr><td>Group A</td></tr><tr><td>Group B</td></tr><tr><td>Group C</td></tr><tr><td>Group D†</td></tr><tr><td>Group E</td></tr></table> | <table><tr><td colspan="2">Lung</td><td colspan="2">Lymph node</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Liver</td><td>Spleen</td><td>Kidney</td><td>Stomach</td><td>Intestine</td><td>Heart</td></tr><tr><td>++*</td><td>+</td><td>++</td><td>+</td><td></td><... |
a7963892cebaca30ad24ae39dfdfcf0475a4bfd56c38f33418f330f673f1f63f.png | complex | <table><tr><td>Haplotype<sup>a</sup></td><td>Controls (%)</td><td colspan="3">Lung cancer</td><td colspan="3">NSCLC</td><td colspan="3">Adenocarcinoma</td></tr><tr><td></td><td></td><td>N (%)</td><td>OR (95%CI)</td><td><i>P</i></td><td>N (%)</td><td>OR (95%CI)</td><td><i>P</i></td><td>N (%)</td><td>OR (95%CI)</td><td><... | <table><tr><td>Haplotypea</td><td>Controls (%)</td><td colspan="3">Lung cancer</td><td colspan="3">NSCLC</td><td colspan="3">Adenocarcinoma</td></tr><tr><td></td><td></td><td>N (%)</td><td>OR (95%CI)</td><td>P</td><td>N (%)</td><td>OR (95%CI)</td><td>P</td><td>N (%)</td><td>OR (95%CI)</td><td>P</td></tr><tr><td>CC</td>... | <table><tr><td>Haplotypea</td><td>Controls (%)</td><td colspan="3">Lung cancer</td><td colspan="3">NSCLC</td><td colspan="3">Adenocarcinoma</td></tr><tr><td></td><td></td><td>N (%)</td><td>OR (95%CI)</td><td>P</td><td>N (%)</td><td>OR (95%CI)</td><td>P</td><td>N (%)</td><td>OR (95%CI)</td><td>P</td></tr><tr><td>TC</td>... |
a411a26014323c8d1c1cc4adb4e3ebb5116cf7fa9d7a2085f71e33b89ec56e90.png | complex | <table><tr><td>DATASET</td><td>ALL</td><td>GA-FS</td><td>H-MTL</td><td>GA-MTL</td><td>GA-MTL-IR</td><td>e-GA-MTL</td></tr><tr><td colspan="7"><i>M</i> = 2 for ANN</td></tr><tr><td>Breast</td><td>53.1(9.5)</td><td>56.3(8.4)</td><td>59.3(8.8)</td><td>71.9(8.9)</td><td>68.8(8.1)</td><td>71.9(8.6)</td></tr><tr><td>Colon</t... | <table><tr><td>DATASET</td><td>ALL</td><td>GA-FS</td><td>H-MTL</td><td>GA-MTL</td><td>GA-MTL-IR</td><td>e-GA-MTL</td></tr><tr><td colspan="7">M = 2 for ANN</td></tr><tr><td>Breast</td><td>53.1(9.5)</td><td>56.3(8.4)</td><td>59.3(8.8)</td><td>71.9(8.9)</td><td>68.8(8.1)</td><td>71.9(8.6)</td></tr><tr><td>Colon</td><td>5... | <table><tr><td>DATASET</td><td>ALL</td><td>GA-FS</td><td>H-MTL</td><td>GA-MTL</td><td>GA-MTL-IR</td><td>e-GA-MTL</td></tr><tr><td>ukemia</td><td>3)</td><td>9.0)</td><td>)</td><td>8.4)</td><td>1)</td><td>0.7(8.9)</td></tr><tr><td>Ovarian</td><td>57.1(6.4)</td><td>67.9(7.4)</td><td>75.0(5.4)</td><td>78.6(5.9)</td><td>79.... |
e5efffba4e91bddc1255c0c61c9089d62f84250d02c954465a1edc39f4d20f2b.png | complex | <table><tr><td></td><td colspan="4">Transplanted organ (n)</td><td colspan="5">EAS characteristics and outcomes</td></tr><tr><td>Authors, Year</td><td>Liver</td><td>Heart</td><td>Lung</td><td>Kidney</td><td>Patients undergoing EAS (n)</td><td>EAS Rate (%)</td><td>Surgical procedures (n)</td><td>Morbidity [n (%)]</td><t... | <table><tr><td></td><td colspan="4">Transplanted organ (n)</td><td colspan="5">EAS characteristics and outcomes</td></tr><tr><td>Authors, Year</td><td>Liver</td><td>Heart</td><td>Lung</td><td>Kidney</td><td>Patients undergoing EAS (n)</td><td>EAS Rate (%)</td><td>Surgical procedures (n)</td><td>Morbidity [n (%)]</td><t... | <table><tr><td></td><td colspan="4">Transplanted organ (n)</td><td colspan="5">EAS characteristics and outcomes</td></tr><tr><td>Authors, Year</td><td>Liver</td><td>Heart</td><td>Lung</td><td>Kidney</td><td>Patients undergoing EAS (n)</td><td>EAS Rate (%)</td><td>Surgical procedures (n)</td><td>Morbidity [n (%)]</td><t... |
d9d92c6a1827de3c7d24b3a933e888952e763a1fd2cd1557150699be1425a965.png | simple | <table><tr><td> </td><td>Women</td><td> </td><td>Test for group difference</td><td>Sign.</td><td>Effect size</td><td>Men</td><td> </td><td>Test for group difference</td><td>Sign.</td><td>Effect size</td></tr><tr><td>Subscale</td><td><i>n</i></td><td><i>M(SD)</i></td><td><i>t</i></td><td><i>p</i></td><td><i>d</i></td><t... | <table><tr><td></td><td>Women</td><td></td><td>Test for group difference</td><td>Sign.</td><td>Effect size</td><td>Men</td><td></td><td>Test for group difference</td><td>Sign.</td><td>Effect size</td></tr><tr><td>Subscale</td><td>n</td><td>M(SD)</td><td>t</td><td>p</td><td>d</td><td>n</td><td>M(SD)</td><td>t</td><td>p<... | <table><tr><td>Sexual arousal</td><td></td><td></td><td>21.01</td><td><0.001</td><td>1.459</td><td></td><td></td><td>16.96</td><td><0.001</td><td>1.807</td></tr><tr><td>Before cancer</td><td>509</td><td>11.17 (3.01)</td><td></td><td></td><td></td><td>114</td><td>13.69 (1.42)</td><td></td><td></td><td></td></tr><tr><td>... |
c8b7127c98749d4b03378d1f949d306da2ba62a69b369543752c155e221074cd.png | simple | <table><tr><td>ABC subfamily</td><td><i>Bombyx mori</i></td><td><i>Drosophila melanogaster</i></td><td><i>Anopheles gambiae</i></td><td><i>Tribilium castaneum</i></td><td><i>Apis mellifera</i></td><td><i>Homo sapiens</i></td></tr><tr><td>A</td><td>6</td><td>10</td><td>9</td><td>9</td><td>3</td><td>13</td></tr><tr><td>B... | <table><tr><td>ABC subfamily</td><td>Bombyx mori</td><td>Drosophila melanogaster</td><td>Anopheles gambiae</td><td>Tribilium castaneum</td><td>Apis mellifera</td><td>Homo sapiens</td></tr><tr><td>A</td><td>6</td><td>10</td><td>9</td><td>9</td><td>3</td><td>13</td></tr><tr><td>B</td><td>8</td><td>8</td><td>5</td><td>6</... | <table><tr><td>ABC subfamily</td><td>Bombyx mori</td><td>Drosophila melanogaster</td><td>Anopheles gambiae</td><td>Tribilium castaneum</td><td>Apis mellifera</td><td>Homo sapiens</td></tr><tr><td></td><td></td><td>2</td><td>2</td><td></td><td>2</td><td>4</td></tr><tr><td>E</td><td>1</td><td>1</td><td>1</td><td>1</td><t... |
57899e88750309d97d02d38983f83c16d06fb479d72bed5e64f558782c1960c4.png | complex | <table><tr><td></td><td colspan="5">Intervention villages</td><td>Control village</td></tr><tr><td></td><td> Village 12</td><td>Village13</td><td>Village 14</td><td>Village15</td><td>Total</td><td>Chikore</td></tr><tr><td><i>S. haematobium</i></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Numb... | <table><tr><td></td><td colspan="5">Intervention villages</td><td>Control village</td></tr><tr><td></td><td>Village 12</td><td>Village13</td><td>Village 14</td><td>Village15</td><td>Total</td><td>Chikore</td></tr><tr><td>S. haematobium</td><td></td><td></td><td></td><td></td><td></td><td></td></tr></table> | <table><tr><td>Number positive</td><td>5</td><td>5</td><td>4</td><td>8</td><td>22</td><td>10</td></tr><tr><td>Number negative</td><td>98</td><td>58</td><td>42</td><td>57</td><td>255</td><td>69</td></tr><tr><td>Prevalence</td><td>4.9%</td><td>7.9%</td><td>8.7%</td><td>12.3</td><td>7.9%</td><td>12.7%</td></tr><tr><td>S. ... |
d9706a2c893b6d695cdd96b79dc8cb35cea52d73e9ac8cf7e81083e1c5716c85.png | simple | <table><tr><td>Strategy</td><td>Cost</td><td>Incremental cost</td><td>Live births</td><td>Cost per live birth</td><td>ICER vs. eS ET</td><td>ICER vs Embry Dx SET</td></tr><tr><td>eSET</td><td>€14,896</td><td>-</td><td>0.314</td><td> €47,439</td><td></td><td></td></tr><tr><td>Embryo-Dx SET</td><td>€16,... | <table><tr><td>Strategy</td><td>Cost</td><td>Incremental cost</td><td>Live births</td><td>Cost per live birth</td><td>ICER vs. eS ET</td><td>ICER vs Embry Dx SET</td></tr></table> | <table><tr><td>eSET</td><td>€14,896</td><td>-</td><td>0.314</td><td>€47,439</td><td></td><td></td></tr><tr><td>Embryo-Dx SET</td><td>€16,687</td><td>€1,791</td><td>0.43</td><td>€38,807</td><td>€15,439</td><td></td></tr><tr><td>DET</td><td>€18,952</td><td>€2,265</td><td>0.473</td><td>€40,068</td><td>€25,509</td><td>€52,... |
621f19f6c33a9dd815b6a85337c140feb6356ebef8d286cea86668486dcc6e5a.png | complex | <table><tr><td>Dataset</td><td>SNVSniffer(M1)</td><td>VarScan2</td><td>SomaticSniper</td><td>JSM2</td><td>MuTect</td></tr><tr><td colspan="4">Sensitivity (%)</td><td colspan="2"></td></tr><tr><td>T1</td><td>66.86</td><td>38.29</td><td>61.148</td><td>0.001</td><td>91.43</td></tr><tr><td>T2</td><td>82.35</td><td>35.29</t... | <table><tr><td>Dataset</td><td>SNVSniffer(M1)</td><td>VarScan2</td><td>SomaticSniper</td><td>JSM2</td><td>MuTect</td></tr><tr><td colspan="4">Sensitivity (%)</td><td colspan="2"></td></tr><tr><td>T1</td><td>66.86</td><td>38.29</td><td>61.148</td><td>0.001</td><td>91.43</td></tr><tr><td>T2</td><td>82.35</td><td>35.29</t... | <table><tr><td>Dataset</td><td>SNVSniffer(M1)</td><td>VarScan2</td><td>SomaticSniper</td><td>JSM2</td><td>MuTect</td></tr><tr><td>T3</td><td>2.41</td><td>4.30</td><td>1.34</td><td>7.39</td><td>19.27</td></tr><tr><td>T4</td><td>2.91</td><td>5.26</td><td>1.39</td><td>10.00</td><td>24.16</td></tr><tr><td>T5</td><td>2.87</... |
1eab9e608dce0b02c2d5a5cf63c35c98f4295d3b30f93113aee6d8b706b90b56.png | simple | <table><tr><td>Maternal Characteristics</td><td><i>n</i> Without Missing Information</td><td>Adolescents <i>n</i> (%)</td><td>Adult Women <i>n</i> (%)</td><td><i>p</i>-Value *</td></tr><tr><td>Late antenatal visit</td><td>42,855</td><td>614 (30.7)</td><td>5148 (12.6)</td><td><0.001</td></tr><tr><td>BMI, kg/m<sup>2</... | <table><tr><td>Maternal Characteristics</td><td>n Without Missing Information</td><td>Adolescents n (%)</td><td>Adult Women n (%)</td><td>p-Value *</td></tr><tr><td>Late antenatal visit</td><td>42,855</td><td>614 (30.7)</td><td>5148 (12.6)</td><td><0.001</td></tr><tr><td>BMI, kg/m2</td><td>42,751</td><td></td><td></td>... | <table><tr><td>Folic acid intake</td><td>43,191</td><td>866 (42.9)</td><td>22,117 (53.7)</td><td><0.001</td></tr><tr><td>Multivitamin intake</td><td>43,192</td><td>961 (47.6)</td><td>22,332 (54.2)</td><td><0.001</td></tr><tr><td>Infections of kidney in pregnancy 1</td><td>43,327</td><td>762 (37.5)</td><td>13,980 (33.9)... |
e8cd4bc773850339c158d62191422823380150d6eb96030e1b38c0b6271e51ef.png | complex | <table><tr><td>Characteristics</td><td><i>n</i> (%)</td></tr><tr><td>Maternal age (years) </td></tr><tr><td><20</td><td>40 (9.1)</td></tr><tr><td>20–24</td><td>163 (36.9)</td></tr><tr><td>25–29</td><td>144 (32.6)</td></tr><tr><td>30–34</td><td>66 (14.9)</td></tr><tr><td>≥35</td><td>29 (6.6)</... | <table><tr><td>Characteristics</td><td>n (%)</td></tr><tr><td>Maternal age (years)</td><td></td></tr></table> | <table><tr><td><20</td><td>40 (9.1)</td></tr><tr><td>20–24</td><td>163 (36.9)</td></tr><tr><td>25–29</td><td>144 (32.6)</td></tr><tr><td>30–34</td><td>66 (14.9)</td></tr><tr><td>≥35</td><td>29 (6.6)</td></tr><tr><td>Parity</td><td></td></tr><tr><td>0</td><td>139 (31.5)</td></tr><tr><td>≥1</td><td>303 (68.6)</td></tr><t... |
1849e8499ae7489bfd59b19718d21be2a5c6228fc7758bf246553c3c88c1b57c.png | complex | <table><tr><td colspan="2">Intake scenarios</td><td colspan="5">Exposure for different ethyl carbamate concentration scenarios in spirits [ng/kg bw/day]</td></tr><tr><td>Drinks per day</td><td>Volume of spirit consumed [mL]</td><td>Mean</td><td>Median</td><td>90th percentile</td><td>95th percentile</td><td>99th percent... | <table><tr><td colspan="2">Intake scenarios</td><td colspan="5">Exposure for different ethyl carbamate concentration scenarios in spirits [ng/kg bw/day]</td></tr><tr><td>Drinks per day</td><td>Volume of spirit consumed [mL]</td><td>Mean</td><td>Median</td><td>90th percentile</td><td>95th percentile</td><td>99th percent... | <table><tr><td>4</td><td>0</td><td></td><td>7</td><td></td><td>3</td><td></td></tr><tr><td>5</td><td>125</td><td>104</td><td>83</td><td>208</td><td>292</td><td>458</td></tr></table> |
fff127fbe8e9d30b2888e45fcf0928f67d2f7f9a23ebdede492fa2e98fac9603.png | complex | <table><tr><td rowspan="2"></td><td colspan="2">ELISA titer anti-STn</td><td>ELISA titer anti-modified-STn</td></tr><tr><td>IgG</td><td>IgM</td><td>IgG</td></tr><tr><td>KLH</td><td>< 100</td><td>< 100</td><td>------</td></tr><tr><td>1-KLH</td><td>15309</td><td>< 100</td><td>15309</td></tr><tr><td>2-KLH</td><td... | <table><tr><td rowspan="2"></td><td>ELISA titer anti-STn</td></tr><tr><td>IgG</td></tr><tr><td>KLH</td><td>< 100</td></tr><tr><td>1-KLH</td><td>15309</td></tr><tr><td>2-KLH</td><td>293812</td></tr><tr><td>3-KLH</td><td>7384</td></tr><tr><td>4-KLH</td><td>555186</td></tr></table> | <table><tr><td>ELISA titer anti-STn</td><td>ELISA titer anti-modified-STn</td></tr><tr><td>IgM</td><td>IgG</td></tr><tr><td>< 100</td><td>------</td></tr><tr><td>< 100</td><td>15309</td></tr><tr><td>< 100</td><td>588662</td></tr><tr><td>< 100</td><td>14794</td></tr><tr><td>< 100</td><td>1061530</td></tr></table> |
5a9c0511b4a8bf030065bfb824ce89c2767088426c2e3d0852b3da1f43dfbc46.png | simple | <table><tr><td>Complication</td><td>Total vivax</td><td>Total patients with severity sign</td><td>Pooled prevalence, %</td><td>95% CI, %</td></tr><tr><td>Death</td><td>46411</td><td>353</td><td>0.3</td><td>0.1–0.4</td></tr><tr><td>Cerebral malaria</td><td>45845</td><td>532</td><td>0.8</td><td>0.5–1.1</td></... | <table><tr><td>Complication</td><td>Total vivax</td><td>Total patients with severity sign</td><td>Pooled prevalence, %</td><td>95% CI, %</td></tr><tr><td>Death</td><td>46411</td><td>353</td><td>0.3</td><td>0.1–0.4</td></tr><tr><td>Cerebral malaria</td><td>45845</td><td>532</td><td>0.8</td><td>0.5–1.1</td></tr><tr><td>M... | <table><tr><td>Circulatory collapse/Shock</td><td>46411</td><td>67</td><td>5.1</td><td>2.5–7.7</td></tr><tr><td>Severe anaemia</td><td>46411</td><td>2276</td><td>4</td><td>2.9–5.1</td></tr><tr><td>Severe thrombocytopenia</td><td>45775</td><td>888</td><td>8.6</td><td>5.4–11.8</td></tr></table> |
c0815c039c9f660efd8e2c6c8ad5a509e3dbc6287e6a5a8fa2a126cf738b05c5.png | simple | <table><tr><td>Phase</td><td>Start-up</td><td>Adaptation</td><td>HRT 24</td><td>HRT 18</td><td>HRT 12</td></tr><tr><td>Days (d)</td><td>1–58 d (58 d)</td><td>59–151 d (93 d)</td><td>152–185 d (34 d)</td><td>186–240 d (55 d)</td><td>241–297 d (57)</td></tr><tr><td>Benzothiazole (mg/L)</td><... | <table><tr><td>Phase</td><td>Start-up</td><td>Adaptation</td><td>HRT 24</td><td>HRT 18</td><td>HRT 12</td></tr><tr><td>Days (d)</td><td>1–58 d (58 d)</td><td>59–151 d (93 d)</td><td>152–185 d (34 d)</td><td>186–240 d (55 d)</td><td>241–297 d (57)</td></tr><tr><td>Benzothiazole (mg/L)</td><td>0</td><td>1–50</td><td>50</... | <table><tr><td>HRT (h)</td><td>24</td><td>24</td><td>24</td><td>18</td><td>12</td></tr><tr><td>Temperature (°C)</td><td>35</td><td>35</td><td>35</td><td>35</td><td>35</td></tr><tr><td>OLR (kg COD/m3·d)</td><td>3.33</td><td>3.26</td><td>3.13</td><td>4.64</td><td>6.36</td></tr></table> |
16589b27e34b1710df15f988de060854c0717aed3c1c05af12916a413a98c18a.png | complex | <table><tr><td> </td><td colspan="5"><i>K</i><sub>A</sub> (μM)<sup>a</sup></td></tr><tr><td>Comp.H</td><td>hCA I</td><td>hCA II</td><td>hCA IV</td><td>hCA VII</td><td>hCA IX</td></tr><tr><td>1</td><td>18.4</td><td>54.2</td><td>47.1</td><td>20.6</td><td>31.4</td></tr><tr><td>2</td><td>1.60</td><td>21.7</td><td>0.00... | <table><tr><td></td><td colspan="5">KA (μM)a</td></tr><tr><td>Comp.H</td><td>hCA I</td><td>hCA II</td><td>hCA IV</td><td>hCA VII</td><td>hCA IX</td></tr><tr><td>1</td><td>18.4</td><td>54.2</td><td>47.1</td><td>20.6</td><td>31.4</td></tr><tr><td>2</td><td>1.60</td><td>21.7</td><td>0.0018</td><td>21.9</td><td>7.81</td></... | <table><tr><td></td><td colspan="5">KA (μM)a</td></tr><tr><td>Comp.H</td><td>hCA I</td><td>hCA II</td><td>hCA IV</td><td>hCA VII</td><td>hCA IX</td></tr><tr><td></td><td>85</td><td>6.8</td><td>24</td><td>.81</td><td>5.8</td></tr><tr><td>4</td><td>0.24</td><td>37.9</td><td>1.03</td><td>0.052</td><td>39.9</td></tr><tr><t... |
6b70079b6001d8b301542cf047572b7c53ca445856d2ef79221634f267a4e60f.png | complex | <table><tr><td> </td><td>Recovered (N = 20)</td><td>Non-recovered (N = 21)</td><td>p-value</td></tr><tr><td>Age (years)</td><td>62.0 (51.8 - 79.8)</td><td>67 (56.4 - 75.5)</td><td>0.860</td></tr><tr><td>Creatinine at admission (mg/dL)</td><td>1.0 (0.8 - 1.4)</td><td>1.0 (0.8 - 1.4)</td><td>0.860</td></tr><tr><td>Glomer... | <table><tr><td></td><td>Recovered (N = 20)</td><td>Non-recovered (N = 21)</td><td>p-value</td></tr><tr><td>Age (ye</td><td>62.0 </td><td>67 (</td><td>0.860</td></tr></table> | <table><tr><td>ars)</td><td>(51.8 - 79.8)</td><td>56.4 - 75.5)</td><td></td></tr><tr><td>Creatinine at admission (mg/dL)</td><td>1.0 (0.8 - 1.4)</td><td>1.0 (0.8 - 1.4)</td><td>0.860</td></tr><tr><td>Glomerular filtration rate, MDRD (mL/min)</td><td>69.5 (46.0 - 99.5)</td><td>72.0 (42.5 - 89.5)</td><td>0.835</td></tr><... |
5e90d685572ee5d37754105dbfc5f9407a94d61cebb642817817a61127b6e80e.png | complex | <table><tr><td rowspan="2">Approach</td><td colspan="3">Accuracy (%)</td></tr><tr><td>Precision</td><td>Recall</td><td>F1 Score</td></tr><tr><td>Hierarchical MEMM [39]</td><td>67.9</td><td>55.5</td><td>61.08</td></tr><tr><td>3D SMoSIFT [1]</td><td>74.8</td><td>65.8</td><td>70.01</td></tr><tr><td>Ni et al., 2013 [46]</t... | <table><tr><td rowspan="2">Approach</td><td colspan="3">Accuracy (%)</td></tr><tr><td>Precision</td><td>Recall</td><td>F1 Score</td></tr><tr><td>Hierarchical MEMM [39]</td><td>67.9</td><td>55.5</td><td>61.08</td></tr><tr><td>3D SMoSIFT [1]</td><td>74.8</td><td>65.8</td><td>70.01</td></tr><tr><td>Ni et al., 2013 [46]</t... | <table><tr><td>[43]</td><td>.2</td><td></td><td>9</td></tr><tr><td>Parisi et al., 2015 [44]</td><td>91.9</td><td>90.2</td><td>91.47</td></tr><tr><td>DBMM [45]</td><td>91.1</td><td>91.9</td><td>91.50</td></tr><tr><td>Proposed feature (ALSTF)</td><td>89.7</td><td>86.1</td><td>87.86</td></tr></table> |
2b43c689f54d73d6c97b55e63bfeee5b480a069140df4324d268c3d2be3a1cfe.png | simple | <table><tr><td>Methods</td><td>Our algorithm</td><td>Traditional method</td></tr><tr><td>Computation time (s)</td><td>163</td><td>217</td></tr><tr><td>MSE</td><td>4.39 × 10<sup>-4</sup></td><td>4.79 × 10<sup>-4</sup></td></tr></table> | <table><tr><td>Methods</td><td>Our algorithm</td><td>Traditional method</td></tr><tr><td>Computation time (s)</td><td>163</td><td>217</td></tr></table> | <table><tr><td>MSE</td><td>4.39 × 10-4</td><td>4.79 × 10-4</td></tr></table> |
13f7d122d9c42939e168f9544a9741cdf735654a7aaea5d38b0bcc303470fa1c.png | simple | <table><tr><td></td><td>Three weeks before treatment</td><td>Penultimate treatment day</td><td>Last treatment day</td><td>Reference data (n = 74 *)</td></tr><tr><td>Treated</td><td>2.72</td><td>2.67</td><td>2.99</td><td>2.43 ± 0.56 </td></tr><tr><td>Control</td><td>3.09</td><td>2.09</td><td>2.69</td><td>2.43 ±... | <table><tr><td></td><td>Three weeks before treatment</td><td>Penultimate treatment day</td><td>Last treatment day</td><td>Reference data (n = 74 *)</td></tr></table> | <table><tr><td>Treated</td><td>2.72</td><td>2.67</td><td>2.99</td><td>2.43 ± 0.56</td></tr><tr><td>Control</td><td>3.09</td><td>2.09</td><td>2.69</td><td>2.43 ± 0.56</td></tr></table> |
96c8768f9aa828cd3dce307c28a3ec8f8b1cf85663b2bc9dedb417bf6cb1b662.png | simple | <table><tr><td>FP</td><td>Metrics</td><td>BCF R<sup>2</sup></td><td>BCF RMSE</td><td>LogP R<sup>2</sup></td><td>LogP RMSE</td><td>DES</td><td>UTI</td></tr><tr><td>Extended</td><td>37</td><td>0.546</td><td>0.917</td><td>0.775</td><td>0.872</td><td>0.970</td><td>0.971</td></tr><tr><td>Extended</td><td>34</td><td>0.546</t... | <table><tr><td>FP</td><td>Metrics</td><td>BCF R2</td><td>BCF RMSE</td><td>LogP R2</td><td>LogP RMSE</td><td>DES</td><td>UTI</td></tr><tr><td>Extended</td><td>37</td><td>0.546</td><td>0.917</td><td>0.775</td><td>0.872</td><td>0.970</td><td>0.971</td></tr><tr><td>Extended</td><td>34</td><td>0.546</td><td>0.919</td><td>0.... | <table><tr><td>FP</td><td>Metrics</td><td>BCF R2</td><td>BCF RMSE</td><td>LogP R2</td><td>LogP RMSE</td><td>DES</td><td>UTI</td></tr><tr><td></td><td>8</td><td>2</td><td></td><td>77</td><td>869</td><td>65</td><td>965</td></tr><tr><td>Pubchem</td><td>28</td><td>0.541</td><td>0.906</td><td>0.772</td><td>0.870</td><td>0.9... |
1b50ec1207b76d9f0835cdab0c43138d624a01309f9ab9ef8f7596b09a1f0bc6.png | simple | <table><tr><td>Diseases</td><td>BBB proteins and affected mechanisms</td></tr><tr><td>Alzheimer's disease</td><td>BBB disruption and permit peripheral IgG to brain. Decrease P-gp and accumulate amyloid-<i>β</i> in brain [67].</td></tr><tr><td>Parkinson's disease</td><td>BBB disruption increases therapeutic agent c... | <table><tr><td>Diseases</td><td>BBB proteins and affected mechanisms</td></tr></table> | <table><tr><td>Alzheimer's disease</td><td>BBB disruption and permit peripheral IgG to brain. Decrease P-gp and accumulate amyloid-β in brain [67].</td></tr><tr><td>Parkinson's disease</td><td>BBB disruption increases therapeutic agent concentration and reduces efficacy of Pgp [6].</td></tr><tr><td>Stroke</td><td>Astro... |
bf0a1fa52e90ecafdfa2e450683e7703c67955c6fdf4745bdaf3fb0091594a97.png | complex | <table><tr><td></td><td colspan="6">MOI</td></tr><tr><td></td><td>1</td><td>10</td><td>50</td><td>100</td><td>500</td><td>1000</td></tr><tr><td>Infection rates</td><td>0.47 ± 0.04</td><td>5.83 ± 0.07</td><td>10.65 ± 0.11</td><td>16.19 ± 0.31</td><td>20.27 ± 0.52</td><td>30.42 ± 2.31</td></... | <table><tr><td></td><td colspan="6">MOI</td></tr><tr><td></td><td>1</td><td>10</td><td>50</td><td>100</td><td>500</td><td>1000</td></tr></table> | <table><tr><td>Infection rates</td><td>0.47 ± 0.04</td><td>5.83 ± 0.07</td><td>10.65 ± 0.11</td><td>16.19 ± 0.31</td><td>20.27 ± 0.52</td><td>30.42 ± 2.31</td></tr><tr><td>Survivil rates</td><td>90.33 ± 1.21</td><td>85.27 ± 1.37</td><td>82.11 ± 1.63</td><td>81 ± 1.42</td><td>62.23 ± 2.15</td><td>40.25 ± 2.13</td></tr><... |
1c552b104123fef0671a82759342d9893fb265a94867ef72fd32dbec4793bf72.png | simple | <table><tr><td>Combinations</td><td>Sensitivity(%)</td><td>Specificity(%)</td><td>PPV(%)</td><td>NPV(%)</td></tr><tr><td>YKL-40</td><td>70.21</td><td>84.13</td><td>62.26</td><td>88.33</td></tr><tr><td>CEA</td><td>10.64</td><td>96.80</td><td>55.56</td><td>74.23</td></tr><tr><td>CYFRA21-1</td><td>40.43</td><td>92.06</td>... | <table><tr><td>Combinations</td><td>Sensitivity(%)</td><td>Specificity(%)</td><td>PPV(%)</td></tr><tr><td>YKL-40</td><td>70.21</td><td>84.13</td><td>62.26</td></tr><tr><td>CEA</td><td>10.64</td><td>96.80</td><td>55.56</td></tr><tr><td>CYFRA21-1</td><td>40.43</td><td>92.06</td><td>65.52</td></tr><tr><td>YKL-40 or CEA</t... | <table><tr><td>NPV(%)</td></tr><tr><td>88.33</td></tr><tr><td>74.23</td></tr><tr><td>80.56</td></tr><tr><td>88.14</td></tr><tr><td>90.74</td></tr><tr><td>81.75</td></tr><tr><td>90.57</td></tr></table> |
c356b3a7e0f37ef648a40cd87e0926b48d8935abf444f4882b5c2a848b8f616f.png | simple | <table><tr><td>Variables</td><td>Characteristics</td><td>All (N = 1179)</td><td>Females (N = 486)</td><td>Males (N = 693)</td><td>Chi-square</td></tr><tr><td> </td><td> </td><td>n (%)</td><td>n (%)</td><td>n (%)</td><td>(p-value)</td></tr><tr><td>Age</td><td>Younger (≤ 22 years)</td><td>608 (51.6)</td><td>215 (44... | <table><tr><td>Variables</td><td>Characteristics</td><td>All (N = 1179)</td><td>Females (N = 486)</td></tr><tr><td></td><td></td><td>n (%)</td><td>n (%)</td></tr><tr><td>Age</td><td>Younger (≤ 22 years)</td><td>608 (51.6)</td><td>215 (44.0)</td></tr><tr><td></td><td>Older (> 22 years)</td><td>571 (48.4)</td><td>271 (56... | <table><tr><td>Males (N = 693)</td><td>Chi-square</td></tr><tr><td>n (%)</td><td>(p-value)</td></tr><tr><td>393 (56.9)</td><td><.001</td></tr><tr><td>300 (43.1)</td><td></td></tr><tr><td>402 (58.2)</td><td><.001</td></tr><tr><td>289 (41.8)</td><td></td></tr><tr><td>338 (48.8)</td><td>.009</td></tr><tr><td>355 (51.2)</t... |
494f9a4a5c64f061fe0b03c4c13b43f65054923babb036937bb55ff79dba0d93.png | complex | <table><tr><td rowspan="2">PYD Measure</td><td>Before</td><td>After</td><td rowspan="2">Change</td><td rowspan="2">95% CI</td><td rowspan="2"><i>t (p)</i></td></tr><tr><td>Mean (SD)</td><td>Mean (SD)</td></tr><tr><td>Caring</td><td>69.99 (16.67)</td><td>71.49 (18.55)</td><td>1.51</td><td>−7.71, 10.73</td><td>0.34... | <table><tr><td rowspan="2">PYD Measure</td><td>Before</td><td>After</td><td rowspan="2">Change</td><td rowspan="2">95% CI</td><td rowspan="2">t (p)</td></tr><tr><td>Mean (SD)</td><td>Mean (SD)</td></tr><tr><td>Caring</td><td>69.99 (16.67)</td><td>71.49 (18.55)</td><td>1.51</td><td>−7.71, 10.73</td><td>0.34 (0.74)</td><... | <table><tr><td>Connection</td><td>78.24 (11.00)</td><td>77.67 (9.94)</td><td>- 0.57</td><td>−6.44, 5.31</td><td>−0.20 (0.84)</td></tr><tr><td>Confidence</td><td>82.58 (12.87)</td><td>74.69 (12.79)</td><td>−7.89</td><td>−16.09, 0.30</td><td>−2.02 (0.06)</td></tr></table> |
5be2e0c1fdaae6cd62d675dbf1c7056cfb1c86d60375d9460c854683bf958820.png | complex | <table><tr><td></td><td colspan="2">Control group (<i>N</i> = 23)</td><td colspan="2">CBT group (<i>N</i> = 25)</td><td colspan="2">CBT with drink group (<i>N</i> = 24)</td><td></td></tr><tr><td></td><td>Mean</td><td>SD</td><td>Mean</td><td>SD</td><td>Mean</td><td>SD</td><td>F-values</td></tr><tr><td>POMS-TA</td><td>10... | <table><tr><td></td><td colspan="2">Control group (N = 23)</td><td colspan="2">CBT group (N = 25)</td><td colspan="2">CBT with drink group (N = 24)</td><td></td></tr><tr><td></td><td>Mea</td><td>S</td><td>Me</td><td>SD</td><td>M</td><td>SD</td><td>F-values</td></tr></table> | <table><tr><td></td><td>n</td><td>D</td><td>an</td><td></td><td>ean</td><td></td><td></td></tr><tr><td>POMS-TA</td><td>10.09</td><td>5.23</td><td>14.84</td><td>8.76</td><td>13.83</td><td>7.23</td><td>2.81†</td></tr><tr><td>POMS-D</td><td>7.09</td><td>8.49</td><td>11.96</td><td>12.32</td><td>12.04</td><td>11.55</td><td>... |
1c7434855d73824a0d8f239a3b644b0eba8207a1901e1f8289fff86e2ba45cad.png | simple | <table><tr><td></td><td>All patients (<i>n</i> = 121)</td><td>mRS = 0–1 (<i>n</i> = 75)</td><td>mRS = 2–6 (<i>n</i> = 46)</td><td><i>P</i>-value</td></tr><tr><td>Age (mean ± SD)</td><td>63.4 ± 11.3</td><td>63.2 ± 10.5</td><td>63.8 ± 12.6</td><td>0.769</td></tr><tr><td>Sex, <i>n</i>(%)</t... | <table><tr><td></td><td>All patients (n = 121)</td><td>mRS = 0–1 (n = 75)</td><td>mRS = 2–6 (n = 46)</td><td>P-value</td></tr><tr><td>Age (mean ± SD)</td><td>63.4 ± 11.3</td><td>63.2 ± 10.5</td><td>63.8 ± 12.6</td><td>0.769</td></tr><tr><td>Sex, n(%)</td><td></td><td></td><td></td><td>0.490</td></tr><tr><td>Men</td><td... | <table><tr><td> infarcts</td><td>2.1)</td><td>.3)</td><td>(23.9)</td><td>0.001</td></tr><tr><td>Borderzone infarcts</td><td>6(5)</td><td>5(6.7)</td><td>1(2.2)</td><td>0.406</td></tr><tr><td>Territorial infarcts</td><td>17(14)</td><td>10(13.3)</td><td>7(15.2)</td><td>0.772</td></tr><tr><td>Perforating artery infarcts pl... |
9c80594295453e726f84a3b6f249c279e93a2df436a5b7b24feb763c5c71eb89.png | simple | <table><tr><td>Device</td><td>Magnitude (%)</td><td>Phase (min)</td></tr><tr><td>Inductive voltage divider</td><td>0.0002</td><td>0.069</td></tr><tr><td>Shunt</td><td>0.01</td><td>0.3</td></tr><tr><td>DMM</td><td>0.01</td><td>0.583</td></tr></table> | <table><tr><td>Device</td><td>Magnitude (%)</td><td>Phase (min)</td></tr></table> | <table><tr><td>Inductive voltage divider</td><td>0.0002</td><td>0.069</td></tr><tr><td>Shunt</td><td>0.01</td><td>0.3</td></tr><tr><td>DMM</td><td>0.01</td><td>0.583</td></tr></table> |
0f09d194f8c059fed4cc943896aa5649c87cfb5dc41f440d607839d63f3dc8d4.png | simple | <table><tr><td></td><td>Moroccan N = 14,490</td><td>Turkish N = 10,316</td><td>Surinamese N = 8,619</td><td>Moluccan N = 1,064</td><td>Dutch N = 33,725</td><td><i>p</i>-value</td></tr><tr><td>Total costs (mean, SE)</td><td>3049.8 (67.3)<sup>4</sup></td><td>3149.4 (79.6)<sup>4</sup></td><td>3843.4 (87.2)<sup>4</sup></td... | <table><tr><td></td><td>Moroccan N = 14,490</td><td>Turkish N = 10,316</td><td>Surinamese N = 8,619</td><td>Moluccan N = 1,064</td><td>Dutch N = 33,725</td><td>p-value</td></tr><tr><td>Total costs (mean, SE)</td><td>3049.8 (67.3)4</td><td>3149.4 (79.6)4</td><td>3843.4 (87.2)4</td><td>2300.0 (247.9)4</td><td>3473.3 (44.... | <table><tr><td>Physical therapy (mean, SE)7</td><td>141.3 (3.4)4</td><td>139.3 (4.1)4</td><td>186.4 (4.5)</td><td>122.5 (12.7)4</td><td>176.7 (2.3)</td><td><0.0001</td></tr><tr><td>Hospital services (mean, SE)8</td><td>1854.3 (59.6)4</td><td>1922.7 (70.5)4</td><td>2478.0 (77.2)</td><td>1472.1 (219.5)4</td><td>2303.6 (3... |
1b4a8482710ba607e4a44e169222b2936370709368d1e050a0137a7def668088.png | complex | <table><tr><td rowspan="2">Year</td><td colspan="5">Host age</td></tr><tr><td>Site</td><td><i>N</i></td><td>1</td><td>2</td><td>3</td></tr><tr><td rowspan="3">2002</td><td>Urwitałt</td><td>64</td><td>0.0 (0.0–23.8)</td><td>0.0 (0.0–13.4)</td><td>0.0 (0.0–13.4)</td></tr><tr><td>Tałty</td><td>... | <table><tr><td rowspan="2">Year</td><td colspan="3">Host age</td></tr><tr><td>Site</td><td>N</td><td>1</td></tr><tr><td rowspan="3">2002</td><td>Urwitałt</td><td>64</td><td>0.0 (0.0–23.8)</td></tr><tr><td>Tałty</td><td>70</td><td>4.5 (0.2–22.2)</td></tr><tr><td>Pilchy</td><td>69</td><td>0.0 (0.0–17.6)</td></tr><tr><td>... | <table><tr><td colspan="2">Host age</td></tr><tr><td>2</td><td>3</td></tr><tr><td>0.0 (0.0–13.4)</td><td>0.0 (0.0–13.4)</td></tr><tr><td>6.5 (1.9–17.4)</td><td>17.6 (5.0–41.7)</td></tr><tr><td>11.5 (3.2–30.4)</td><td>8.3 (1.5–26.7)</td></tr><tr><td></td><td>5.4 (3.7–7.8)</td></tr><tr><td>4.5 (0.7–17.7)</td><td>4.0 (0.2... |
3cbc413231e9d16ec0a3c8bdcab4b0727ffb2710f2344d16329af1d91a54081e.png | simple | <table><tr><td></td><td></td><td>Cases(n)</td><td>Ref(n)</td><td>Odds ratio*</td><td>Confidence interval (95%)</td></tr><tr><td>Household economy</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Non-poor</td><td>Close</td><td>68</td><td>317</td><td>Ref</td><td></td></tr><tr><td></td><td>Remote</td><td>48</... | <table><tr><td></td><td></td><td>Cases(n)</td><td>Ref(n)</td></tr><tr><td>Household economy</td><td></td><td></td><td></td></tr><tr><td>Non-poor</td><td>Close</td><td>68</td><td>317</td></tr><tr><td></td><td>Remote</td><td>48</td><td>159</td></tr><tr><td>Poor</td><td>Close</td><td>10</td><td>41</td></tr><tr><td></td><t... | <table><tr><td>Odds ratio*</td><td>Confidence interval (95%)</td></tr><tr><td></td><td></td></tr><tr><td>Ref</td><td></td></tr><tr><td>1.40</td><td>0.92 - 2.13</td></tr><tr><td>Ref</td><td></td></tr><tr><td>2.84</td><td>1.30 - 6.21</td></tr><tr><td></td><td></td></tr><tr><td>Ref</td><td></td></tr><tr><td>1.30</td><td>0... |
72bb8858d46f3ecaa1ccb8e7bd4950c549d153e4b0de35a78547cd9ea4c960ae.png | complex | <table><tr><td></td><td></td><td colspan="4">Men</td><td colspan="4">Women</td></tr><tr><td></td><td></td><td colspan="2">IHD mortality</td><td colspan="2">Stroke mortality</td><td colspan="2">IHD mortality</td><td colspan="2">Stroke mortality</td></tr><tr><td></td><td>Median</td><td>Age-adjusted HR</td><td>Multivariat... | <table><tr><td></td><td></td><td colspan="4">Men</td><td colspan="4">Women</td></tr><tr><td></td><td></td><td colspan="2">IHD mortality</td><td colspan="2">Stroke mortality</td><td colspan="2">IHD mortality</td><td colspan="2">Stroke mortality</td></tr><tr><td></td><td>Median</td><td>Age-adjusted HR</td><td>Multivariat... | <table><tr><td></td><td></td><td colspan="4">Men</td><td colspan="4">Women</td></tr><tr><td></td><td></td><td colspan="2">IHD mortality</td><td colspan="2">Stroke mortality</td><td colspan="2">IHD mortality</td><td colspan="2">Stroke mortality</td></tr><tr><td></td><td>Median</td><td>Age-adjusted HR</td><td>Multivariat... |
386aae8b0ca942e879975a030f948934022d46fc2c0ff77f83b045ef09b016ca.png | simple | <table><tr><td></td><td><i>n</i></td><td>Mean (SD) or %</td></tr><tr><td>Age</td><td>5052</td><td>46.0 (9.0)</td></tr><tr><td>Job seniority</td><td>4979</td><td>8.6 (7.1)</td></tr><tr><td>BMI</td><td></td><td></td></tr><tr><td> Normal</td><td>2842</td><td>58.8%</td></tr><tr><td> Overweight</td><td>1415</td><td>29.3%</t... | <table><tr><td></td><td>n</td><td>Mean (SD) or %</td></tr><tr><td>Age</td><td>5052</td><td>46.0 (9.0)</td></tr></table> | <table><tr><td>Job seniority</td><td>4979</td><td>8.6 (7.1)</td></tr><tr><td>BMI</td><td></td><td></td></tr><tr><td>Normal</td><td>2842</td><td>58.8%</td></tr><tr><td>Overweight</td><td>1415</td><td>29.3%</td></tr><tr><td>Obese</td><td>577</td><td>11.9%</td></tr><tr><td>Smoking</td><td>1776</td><td>35.5%</td></tr><tr><... |
741a2452573d32e054af768c11c44b90e0e5d8f99d893dc6389c015a53afb7b5.png | complex | <table><tr><td colspan="4"> </td><td>Astrocytoma</td><td>Medulloblastoma</td><td>Craniopharyngioma</td><td>Germ cell tumors</td><td>Ependymal tumours</td></tr><tr><td>Country</td><td>Author</td><td>Period</td><td>Age(yrs)</td><td colspan="5"> </td></tr><tr><td>China</td><td> </td><td>1990-2009</td><td>0-19</td><td>29.2... | <table><tr><td colspan="4"></td><td>Astrocytoma</td><td>Medulloblastoma</td><td>Craniopharyngioma</td><td>Germ cell tumors</td><td>Ependymal tumours</td></tr><tr><td>Country</td><td>Author</td><td>Period</td><td>Age(yrs)</td><td colspan="5"></td></tr><tr><td>China</td><td></td><td>1990-2009</td><td>0-19</td><td>29.2%</... | <table><tr><td>India</td><td>Asirvatham et al. [8]</td><td>1990-2004</td><td>0-18</td><td>49.7%</td><td>12.0%</td><td>10.3%</td><td>3.0%</td><td>5.2%</td></tr><tr><td>France</td><td>Bauchet et al. [9]</td><td>2004-2006</td><td>0-19</td><td>32.9%</td><td>13.1%</td><td>5.4%</td><td>3.6%</td><td>8.6%</td></tr><tr><td>Braz... |
9adc8fe99bef9703d87a66b7c9341f500489640d155272da8913e664b34d8d35.png | complex | <table><tr><td></td><td>Tiotropium</td><td>Control</td><td>Hazard ratio(tiotropium versus control)*(95% CI)</td></tr><tr><td colspan="4">Time to first exacerbation, median month</td></tr><tr><td>Q1</td><td>19.4</td><td>14.6</td><td>0.80 (0.70 to 0.92)</td></tr><tr><td>Q2</td><td>22.4</td><td>13.6</td><td>0.83 (0.73 to ... | <table><tr><td></td><td>Tiotropium</td><td>Control</td><td>Hazard ratio(tiotropium versus control)*(95% CI)</td></tr><tr><td colspan="4">Time to first exacerbation, median month</td></tr><tr><td>Q1</td><td>19.4</td><td>14.6</td><td>0.80 (0.70 to 0.92)</td></tr><tr><td>Q2</td><td>22.4</td><td>13.6</td><td>0.83 (0.73 to ... | <table><tr><td colspan="4">o first exacerbation leading to hospitalization (first quartile), month</td></tr><tr><td>Q1</td><td>NA</td><td>39.9</td><td>0.72 (0.57 to 0.91)</td></tr><tr><td>Q2</td><td>47.2</td><td>32.5</td><td>0.73 (0.59 to 0.90)</td></tr><tr><td>Q3</td><td>37.0</td><td>40.2</td><td>1.05 (0.86 to 1.30)</... |
19d864d3f194e059d0556a35301f79dd377cf010faaa56e1fc8788105f7777c0.png | simple | <table><tr><td>Node name</td><td>Links</td><td>Links in background</td><td>Links to seed</td><td>Links in subnetwork</td><td><i>z</i>-score</td></tr><tr><td>FUT4</td><td>3</td><td>11429</td><td>2</td><td>29</td><td>22.86</td></tr><tr><td>ICAM5</td><td>4</td><td>11429</td><td>2</td><td>29</td><td>19.77</td></tr><tr><td>... | <table><tr><td>Node name</td><td>Links</td><td>Links in background</td><td>Links to seed</td><td>Links in subnetwork</td></tr><tr><td>FUT4</td><td>3</td><td>11429</td><td>2</td><td>29</td></tr><tr><td>ICAM5</td><td>4</td><td>11429</td><td>2</td><td>29</td></tr><tr><td>PRTN3</td><td>9</td><td>11429</td><td>2</td><td>29<... | <table><tr><td>z-score</td></tr><tr><td>22.86</td></tr><tr><td>19.77</td></tr><tr><td>13.10</td></tr><tr><td>12.47</td></tr><tr><td>12.41</td></tr><tr><td>10.25</td></tr><tr><td>10.06</td></tr><tr><td>9.93</td></tr><tr><td>8.23</td></tr><tr><td>8.23</td></tr><tr><td>7.86</td></tr><tr><td>6.42</td></tr><tr><td>2.13</td>... |
ff6136a38cf0d0e9c85135b4bb6e8bd9511ee20d1adf035299b47bfa5fdaab29.png | complex | <table><tr><td colspan="3">Simulated Data</td><td colspan="3">Mediated SEM</td><td colspan="3">Mixed Model without Mediator</td></tr><tr><td>Effect Size</td><td>Effect Distribution</td><td>Effect</td><td>Bias (%)</td><td>Coverage Probability (%)</td><td>Power (%)</td><td>Bias (%)</td><td>Coverage Probability (%)</td><t... | <table><tr><td colspan="3">Simulated Data</td><td colspan="3">Mediated SEM</td><td colspan="3">Mixed Model without Mediator</td></tr><tr><td>Effect Size</td><td>Effect Distribution</td><td>Effect</td><td>Bias (%)</td><td>Coverage Probability (%)</td><td>Power (%)</td><td>Bias (%)</td><td>Coverage Probability (%)</td><t... | <table><tr><td colspan="3">Simulated Data</td><td colspan="3">Mediated SEM</td><td colspan="3">Mixed Model without Mediator</td></tr><tr><td></td><td>Indirect</td><td>Total</td><td>0.9</td><td>94</td><td>100</td><td>-0.6</td><td>94</td><td>100</td></tr><tr><td>Medium</td><td>Equal</td><td>Total</td><td>-1.5</td><td>94<... |
538a583877c54c54b73f21ba9c65a3a2286c9f2a0ec35367254e92b0875b6ead.png | simple | <table><tr><td>Clinical parameter</td><td>Vehicle</td><td>SMI 6877002</td><td>Statistics</td></tr><tr><td>Incidence (%)</td><td>100</td><td>100</td><td></td></tr><tr><td>Survival (%)</td><td>100</td><td>100</td><td></td></tr><tr><td>AUC</td><td>10.6</td><td>8.7</td><td><i>P</i> = 0.0804</td></tr><tr><td>Mean clinical s... | <table><tr><td>Clinical parameter</td><td>Vehicle</td><td>SMI 6877002</td><td>Statistics</td></tr><tr><td>Incidence (%)</td><td>100</td><td>100</td><td></td></tr><tr><td>Survival (%)</td><td>100</td><td>100</td><td></td></tr></table> | <table><tr><td>Clinical parameter</td><td>Vehicle</td><td>SMI 6877002</td><td>Statistics</td></tr><tr><td>AUC</td><td>10.6</td><td>8.7</td><td>P = 0.0804</td></tr><tr><td>Mean clinical score (day 13)</td><td>2.9</td><td>2.0</td><td>P = 0.1160</td></tr><tr><td>Mean day of onset</td><td>11.1</td><td>11.5</td><td>P = 0.47... |
db98073afb7f28494ac0e673502bb222e3c7e88dd0d0532a44b9d75596f6877d.png | complex | <table><tr><td rowspan="2">Industry (type of animal)</td><td colspan="2">No. (%)</td></tr><tr><td>Campylobacteriosis</td><td>Cryptosporidiosis</td></tr><tr><td>Total</td><td>557 (100.0)</td><td>93 (100.0)</td></tr><tr><td>Animal production</td><td>380 (68.2)</td><td>73 (78.5)</td></tr><tr><td>(Cattle and other bovines)... | <table><tr><td rowspan="2">Industry (type of animal)</td><td colspan="2">No. (%)</td></tr><tr><td>Campylobacteriosis</td><td>Cryptosporidiosis</td></tr><tr><td>Total</td><td>557 (100.0)</td><td>93 (100.0)</td></tr><tr><td>Animal production</td><td>380 (68.2)</td><td>73 (78.5)</td></tr><tr><td>(Cattle and other bovines)... | <table><tr><td>(Beef cattle processing)</td><td>52 (57.1)</td><td>2 (40.0)</td></tr><tr><td>(Poultry processing)</td><td>13 (14.3)</td><td>0 (—)</td></tr><tr><td>(Swine processing)</td><td>10 (11.0)</td><td>2 (40.0)</td></tr><tr><td>(Multiple animals/Unspecified)</td><td>16 (17.6)</td><td>1 (20.0)</td></tr><tr><td>Vete... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.